Evsjv 'K M Ru: Iwr÷Vw© Bs WW G-1

†iwR÷vW© bs wW G-1
evsjv‡`k †M‡RU
AwZwi³ msL¨v
KZ…©c¶ KZ…©K cÖKvwkZ
e„n¯úwZevi, gvP© 23, 2017
MYcÖRvZš¿x evsjv‡`k miKvi

¯^v¯’¨ I cwievi Kj¨vY gš¿Yvjq
Rb¯^v¯’¨-01 AwakvLv
cÖÁvcb
ZvwiL : 01 ˆPÎ 1423 e½vã/15 gvP© 2017 wLª÷vã
bs mwPe/¯^vcKg/gwš¿cwil`-1/2013-238, ZvwiL : 21-12-2016 wLªt MYcÖRvZš¿x
evsjv‡`k miKv‡ii gwš¿mfv KwgwUi mycvwi‡ki wfwË‡Z Ges gwš¿cwil` wefv‡Mi Aby‡gv`bµ‡g
¯^v¯’¨ I cwievi Kj¨vY gš¿Yvjq wbgœewY©Z ÒRvZxq Jla bxwZ, 2016Ó cÖYqb Kwi‡jb :
ÒRvZxq Jla bxwZ, 2016Ó

1| cÖ¯Ívebv
1.1 MYcÖRvZš¿x evsjv‡`‡ki msweav‡bi 15(K), 15(N) I 18(1) aviv Abyhvqx
evsjv‡`k miKvi Kvh©Ki ¯^v¯’¨‡mev cÖ`v‡bi wel‡q RbM‡Yi Kv‡Q cÖwZkÖæwZe×|
DbœZ ¯^v¯’¨‡mev cÖ`v‡bi Rb¨ DbœZgv‡bi wPwKrmK I wPwKrmv mvgMÖxi cvkvcvwk
cÖ‡qvRb gvbm¤úbœ Jla| Rb¯^v¯’¨ myiÿvi ¯^v‡_© wbivc` Lv`¨ wbwðZKi‡Y Ges
Mevw`cï‡K my¯’ mej ivL‡Z gvbm¤§Z wbivc` †f‡Uwibvwi WªvMm I f¨vKwmb
cÖ‡qvRb|
1.2 evsjv‡`‡ki Jlawkí GKwU `ªæZ weKvkgvb wkíLvZ| GK mgq †hLv‡b Pvwn`vi cÖvq
80% Jla Avg`vwb Kiv nZ †mLv‡b eZ©gv‡b 97% GiI AwaK Jla †`‡kB
Drcvw`Z n‡”Q| evsjv‡`‡k Drcvw`Z ¸YMZgvbm¤úbœ Jla GLb we‡k¦i wewfbœ DbœZ
†`kmn 113wU †`‡k ißvwb n‡”Q| B‡Zvg‡a¨ †ek K‡qKwU †`kxq †Kv¤úvwb
(2941)
g~j¨ t UvKv 56.00
2942 evsjv‡`k †M‡RU, AwZwi³, gvP© 23, 2017
DbœZ †`‡ki Jla wbqš¿YKvix cÖwZôv‡bi wbKU †_‡K Good Manufacturing

Practice (GMP) mb` jvf K‡i‡Q| Jla Drcv`‡bi cÖ‡qvRbxq cÖhyw³ AR©b Kivq
evsjv‡`‡ki Jlawkí eZ©gv‡b cÖPwjZ I DbœZ cÖhyw³-wbf©i cÖvq me ai‡bi †Wv‡mR&
dg©B Drcv`‡b mÿg| †`‡k Jla Drcv`‡bi DbœZ cÖhyw³i cvkvcvwk i‡q‡Q AwfÁ
I `ÿ dvg©vwm÷mn Ab¨vb¨ mswkøó `ÿ Rbkw³| 2009 mvj †_‡K ¯^v¯’¨ †mev‡K›`ª/
myweav m¤úªmvi‡Yi cvkvcvwk ¸YMZgvbm¤úbœ ch©vß cwigv‡Y Jla mieivn Kiv
n‡”Q|
1.3 †`‡k Ily‡ai KuvPvgvj cÖ‡qvR‡bi Zzjbvq A‡bK Kg Drcvw`Z n‡”Q| ZvQvov †`‡ki
gvby‡li Kvh©Ki wPwKrmv †mevi Rb¨ AZ¨vek¨Kxq Jla Drcv`‡bi cwigvY AviI
evov‡bv cª‡qvRb| Jla Drcv`‡b wek¦ ¯^v¯’¨ ms¯’v wb‡`©wkZ GMP K‡Vvifv‡e †g‡b
Pjv, evRv‡i bKj-†fRvj †gqv‡`vËxY©-wbeÜbwenxb-KvD›Uvi‡dBU-wgmeªv‡ÛW I
†PvivPvjvbK…Z Ily‡ai wewµ cÖwZ‡iva Kiv, wek¦ ¯^v¯’¨ ms¯’vi civgk©g‡Zv Ily‡ai
†hŠw³K eënvi wbwðZ Kiv, †`‡k ch©vqµ‡g KwgDwbwU dv‡g©mx cÖwZôv Kiv Ges
mKj eo nvmcvZv‡j nmwcUvj dv‡g©mx Pvjy Kiv Avek¨K| m‡e©vcwi cwiewZ©Z
êwk¦K A_©bxwZi †cÖÿvc‡U †`‡ki Rb¯^v¯’¨ iÿv I Jla ißvwbi cwigvY evov‡Z
wek¦ evwYR¨ ms¯’vi Ô†gav¯^Z¡ I evwYR¨ AvBbÕ ev wUªcm& (Trade Related Aspects
of Intellectual Property Rights - TRIPS) Pzw³i Av‡jv‡K evsjv‡`‡ki Jla
†m±i‡K cÖ¯‘Z Kiv cÖ‡qvRb| eZ©gvb miKvi wbe©vPbx Bk‡Znv‡ii cÖwZkÖæwZ
†gvZv‡eK miKvi MV‡bi ïiæ‡Z RvZxq ¯^v¯’¨ bxwZ, RvZxq RbmsL¨v bxwZ Ges
RvZxq JlabxwZ cÖYq‡b nvZ †`b| RvZxq ¯^v¯’¨ bxwZ, 2011, RvZxq RbmsL¨v
bxwZ, 2012 Gi mv‡_ mvgÄm¨ †i‡L RvZxq JlabxwZ, 2016 cÖYqb Kiv n‡q‡Q|
1.4 m`¨ ¯^vaxbZvcÖvß evsjv‡`‡k Pvwn`vi kZKiv 80 fv‡MiI †ekx Jla Avg`vwb
Ki‡Z nZ| †`‡k Drcvw`Z Ily‡ai g‡a¨ A‡bK ÿwZKi I AcÖ‡qvRbxq Jla
evRv‡i cÖPwjZ wQj| g~jëvb ê‡`wkK gy`ªvi AcPq †iv‡a ¯^vaxbZvi ci RvwZi
RbK e½eÜz †kL gywReyi ingvb 1973 mv‡j †UªwWs K‡c©v‡ikb Ae evsjv‡`‡ki
Aax‡b cÖ‡qvRbxq Jla Avg`vwbi j‡ÿ¨ GKwU †mj MVb K‡ib| Gi gva¨‡g Jla
Avg`vwb Lv‡Z wecyj ê‡`wkK gy`ªvi AcPq eÜ nq| GQvov e½eÜz †`‡k gvbm¤§Z
Ily‡ai Drcv`b evov‡bv Ges G wkí‡K mn‡hvwMZv I wbqš¿‡Yi j‡ÿ¨ 1974 mv‡j
ÔJla cÖkvmb cwi`ßiÕ MVb K‡ib| wZwb Rb¯^v¯’¨ iÿvi ¯^v‡_© wewfbœ we‡`wk
†Kv¤úvwbi †c‡U›UK…Z JlaI †`kxq †Kv¤úvwb KZ…©K Drcv`‡bi Rb¨ Mwie †`k
wn‡m‡e evsjv‡`k‡K †c‡U›U AvB‡bi evB‡i iv‡Lb ; d‡j †`kxq †Kv¤úvwb¸‡jv
wecyj cª‡Yv`bv jvf K‡i Ges cÖwZ‡hvwMZvg~jK evRv‡ii Kvi‡Y RxebiÿvKvix
Ily‡ai `vg K‡g mnRjf¨ n‡q I‡V| Gfv‡e †`‡ki RbMY I †`kxq Jla wkí
Dfq cÿB DcK…Z nq|
evsjv‡`k †M‡RU, AwZwi³, gvP© 23, 2017 2943
1.5 1982 mv‡j evsjv‡`k miKvi cÖ_g RvZxq JlabxwZ cÖYqb K‡i, hv wek¦ ¯^v¯’¨
ms¯’vmn †`kxq I AvšÍR©vwZK ms¯’vmg~n KZ…©K wecyjfv‡e cÖkswmZ I mgv`„Z nq|
G JlabxwZi d‡j evsjv‡`‡ki Ily‡ai wbivcËv wbwðZ nq I gvb DbœZ nq, Ily‡ai
`v‡gi Ici wbqš¿Y cÖwZwôZ nq| Avg`vwb wbf©iZv K‡g †`k Ily‡ai †ÿ‡Î ¯^wbf©i
n‡Z ïiæ K‡i, Jla †m±‡i we‡`wk AvwacZ¨ K‡g Av‡m, †`kxq Jla †Kv¤úvwbmg~n
AvaywbK cÖhyw³mg„× e„n`vKvi KviLvbv ¯’vcb Ki‡Z _v‡K| AvšÍR©vwZK cwigÐ‡j
evsjv‡`‡ki Jla †m±‡ii fveg~wZ© D¾¡j nq Ges GK mgqKvi Jla Avg`vwbKvix
†`kwU Jla ißvwbKvix †`‡k cwiYZ nq|
1.6 2005-Gi evsjv‡`‡ki wØZxq RvZxq JlabxwZ‡Z Jlawk‡íi Rb¨ mnvqK wKQz
D‡`¨vM wQj, wKš‘ G‡Z JlabxwZi CwáZ jÿ¨mg~n AwR©Z nqwb| RbM‡Yi
¯^v_©iÿvi cvkvcvwk evsjv‡`‡ki Jla wk‡íi Rb¨ †`‡k Ges †`‡ki evB‡i m¤¢vebvi
†h †ÿÎ¸‡jv ˆZwi n‡q‡Q †m cÖZ¨vkv¸‡jv aviY K‡i miKvi KZ…©K mg‡qvc‡hvMx
Z…Zxq GKwU RvZxq JlabxwZ cÖYqb Kiv Avek¨K n‡q c‡o‡Q| G j‡ÿ¨ †`‡ki
Jlawkí‡K AviI `vwqZ¡kxj n‡q Jl‡ai Drcv`b I gvb-wbqš¿‡Y wek¦ ¯^v¯’¨ ms¯’v
wb‡`©wkZ wRGgwc bxwZgvjv K‡Vvifv‡e †g‡b Pjvi Dc‡hvMx n‡Z n‡e|
1.7 A¨v‡jvc¨vw_K Jl‡ai cvkvcvwk UªvwWkbvj Jl‡ai †ÿ‡ÎI evsjv‡`‡k D‡jøL‡hvM¨
AMÖMwZ mvwaZ n‡q‡Q| GLb Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I
ev‡qv‡KwgK c×wZi †`kR m¤ú`-wbf©i Gme wkí Zv‡ì wbR¯^ †gŠwjK bxwZ I wek¦
¯^v¯’¨ ms¯’vi GMP Guideline AbymiY K‡i mdjZvi mv‡_ Jla Drcv`‡bi †Póv
Ki‡Q| UªvwWkbvj wPwKrmv c×wZi cÖwZ RbM‡Yi A‡bKvs‡ki AvMÖn Ges UªvwWkbvj
wPwKrmv c×wZ‡K RvZxq ¯^v¯’¨ †mevq Kvh©Kifv‡e AšÍfz©³ Kivi Rb¨ wek¦ ¯^v¯’¨
ms¯’vi mycvwikgvjvi Av‡jv‡K AvaywbK wPwKrmv c×wZi cvkvcvwk Avqy‡e©w`K,
BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jlawkí‡KI GwM‡q Avmvi my‡hvM
†Ìqv cÖ‡qvRb| RvZxq ¯^v¯’¨ bxwZ, 2011 G weKí wPwKrmv c×wZi Dci ¸iæZ¡
cÖ`vb Kiv n‡q‡Q|
1.8 cÖvwYm¤ú` Dbœqb Ges †ivM cÖwZ‡iva I wPwKrmv, wbivc` Lv`¨ wbqš¿Y wbwðZKiY I
cywó †hvMv‡bi j‡ÿ¨ †f‡Uwibvwi Jla I cÖwZ‡laK wUKv Drcv`‡b wek¦ ¯^v¯’¨ ms¯’vi
GMP Guide AbymiY Kiv cÖ‡qvRb|
2| RvZxq JlabxwZi jÿ¨mg~n

2.1| RbMY hv‡Z wbivc`, Kvh©Ki I gvbm¤úbœ Jla mn‡R µqmva¨ g~‡j¨ †c‡Z cv‡i
Zv wbwðZ Kiv|
2.2| Jl‡ai †hŠw³K I wbivc` eënvi Ges myôz cwi‡ekb eë¯’v (Dispensing)
wbwðZ Kiv|
2.3| ¯’vbxq mKj c×wZi Jla cÖ¯‘ZKvix wkímg~n‡K AMÖvwaKvi wfwË‡Z cÖ‡qvRbxq
†mev I my‡hvM-myweav cÖ`vb Kiv, hv‡Z gvbm¤úbœ Jla I Jl‡ai KuvPvgvj
Drcv`‡bi †ÿ‡Î ¯^qsm¤ú~Y©Zv AwR©Z nq|
2.4| †`‡ki Drcvw`Z Jl‡ai ißvwb e„w× Kiv|

2.5| Jl‡ai Kvh©Ki bRi`vix (Surveillance) eë¯’v cÖwZôv Kiv|
3| RvZxq JlabxwZi Dcv`vbmg~n

3.1| Jl‡ai wbivc` eënvi, Kvh©KvwiZv Ges Dc‡hvwMZv wbwðZ Kivi j‡ÿ¨ DbœZ
†`‡ki wbeÜb gvb`‡Ði mv‡_ m½wZ †i‡L wbeÜb cÖwµqv mgq mgq nvjbvMv`
Kiv|
3.2| Jla cÖkvmb Awa`ß‡ii eZ©gvb Rbkw³ I AeKvVv‡gvMZ my‡hvM-myweav
h_vh_fv‡e e„w×i gva¨‡g G‡K RvZxq Jla wbqš¿Y KZ…©cÿ (National
Regulatory Authority-NRA) wn‡m‡e Kvh©Ki Kivi Rb¨ Jla cÖkvmb
Awa`ßi‡K AviI kw³kvjx Kiv| RvZxq Jla wbqš¿YKvix KZ…©cÿ‡K b~¨bZg
WHO (World Health Organisation)-Gi ¯^xK…wZ Ges PIC/s The Pharma-
ceutical Inspection Convention and Pharmaceutical Inspection Co-
operation Scheme)-Gi m`m¨fz³ Kiv|
3.3| bKj, †fRvj, ÿwZKi, wbeÜbwenxb, KvD›Uvi‡dBU (counterfeit), wgmeªv‡ÛW
(misbranded) I wb¤œgv‡bi Jla I †gwW‡Kj wWfvBm cÖ¯‘Z, weµq I weZiY
wbwl× Kiv Ges Abyiƒc Kg©Kv‡Ði Rb¨ `vqx e¨w³‡ì `„óvšÍg~jK kvw¯Í cÖ`vb Kiv|
3.4| Jla wbe©vPb, cwigvY wba©viY, msMÖn, gRy`KiY I weZiY c×wZ †Rvi`vi Kiv,
hv‡Z †`‡ki mKj GjvKvq RbM‡Yi Kv‡Q †m¸‡jv mnRjf¨ nq| Jl‡ai cvBKvwi
†`vKvb ev dv‡g©mxmn mKj ai‡bi Jl‡ai msiÿYvMv‡i ev cwienb I weZiYKv‡j
Jl‡ai gvb Ges myôz cª‡qvM I cwi‡ekb eë¯’v (Dispensing) eRvq ivLvi Rb¨
ZvcgvÎv I Av`ª©Zv wbqš¿Ymn h_vh_ msiÿY c×wZ wbwðZ Kiv|
3.5| me ¯^xK…Z c×wZi Jl‡ai †hŠw³K, Kvh©Ki I wbivc` eënvi wbwðZ Kivi j‡ÿ¨
MYgva¨‡g Jl‡ai mKj iKg weÁvcb I cÖPvi wbqš¿Y Ges A‰bwZK wecYb
(Unethical Marketing) wKsev eû¯Íi wecYb‡iv‡a (Multi Level Marketing)
myôz bxwZgvjv cÖYqb I cÖ‡qvM Kiv|
3.6| myjf g~‡j¨ Jl‡ai mnRjf¨Zv wbwðZ Kiv Ges ¯^”Q I †hŠw³Kfv‡e Jl‡ai g~j¨
wba©viY Kiv| miKvi KZ…©K mg‡q mg‡q ZvwjKvfz³ Jlamg~‡ni g~j¨ wba©viY/
cybtwba©viY c×wZ Ae¨vnZ ivLv|
3.7| †`‡k bZzb cÖhyw³ I KvwiMwi Ávb n¯ÍvšÍ‡ii j‡ÿ¨ be-Avwe®‹…Z A_ev D”P cÖhyw³i
(†hgb-ev‡qv‡UK‡bvjwR) Jl‡ai †ÿ‡Î †`‡k wewb‡qvM, Jla Drcv`b I
evRviRv‡Zi Rb¨ M‡elYvwfwËK we‡`wk Jla Drcv`bKvix cÖwZôvb¸‡jv‡K
DrmvwnZ Kiv| †`‡k bZzb cÖhyw³ I KvwiMwi Ávb n¯ÍvšÍ‡ii h_vh_ wbðqZvmn
evsjv‡`‡k wewb‡qvM, Jla Drcv`b I weµ‡qi Rb¨ M‡elYvwfwËK Jla
cÖ¯‘ZKviKMY‡K DrmvwnZ Kiv|
3.8| Jla Drcv`bKvix‡ì‡K wbR wbR cÖwZôv‡b Kvh©Ki M‡elYv I Dbœq‡b
(Research & Development, R & D) DØy× Kiv| G mKj M‡elYvMv‡ii Rb¨
Avg`vwbK…Z hš¿cvwZi Dci Av‡ivwcZ ïénvi Kgv‡bv, †mB mv‡_ wek¦we`¨vjq,
mÿg M‡elYv ms¯’v I Jla Drcv`bKvix‡ì mgwš^Z †hŠ_ D‡`¨v‡M cÖv‡qvwMZ
M‡elYv (Applied Research) Drmvn †Ìqv| Jla msµvšÍ †gŠwjK I dwjZ
M‡elYv (Basic and Applied Research) Kvh©µg MÖn‡Yi Rb¨ miKvi,
wek¦we`¨vjq, M‡elYv Bbw÷wUDU, mswkøó †ckvRxex Ges cÖ¯‘ZKviKM‡Yi g‡a¨
mn‡hvwMZv‡K DrmvwnZ Kiv|
3.9| Jl‡ai weiƒc cÖwZwµqvi NUbvmg~n h_vh_fv‡e AewnZ Kivi Rb¨ mswkøó mKj‡K
DØy× Kivi gva¨‡g dvg©v‡KvwfwR‡jÝ (Pharmacovigilance) Ges Jl‡ai weiƒc
cÖwZwµqvmg~‡ni (Adverse Drug Reactions - ADR) Dchy³ cwiexÿY wbwðZ
Kiv|
3.10| Jla Drcv`bKvix me ¯^xK…Z c×wZi KviLvbvmg~‡n h_vh_fv‡e Good
Manufacturing Practices (GMP) AbymiY I ev¯Íevq‡bi j‡ÿ¨ Drcv`bKvix
cÖwZôv‡b mswkøó †ckvq `ÿ Rbej wb‡qvM I wbqwgZ cÖwkÿY wbwðZ Kiv|
3.11| †`‡k Drcvw`Z Jl‡ai ißvwb e„w× Kivi Rb¨ miKvwi ch©v‡q cª‡qvRbxq eë¯’v
MÖnY Ges wewfbœ cÖ‡Yv`bv cÖ`vb Kiv|
3.12| (K) Jl‡ai cixÿv I we‡køl‡Yi Rb¨ †K›`ªxq cixÿvMvi wn‡m‡e National
Control Laborotory (NCL)-†K AvaywbKxKiY I ch©vqµ‡g me wefv‡M
†K›`ªxq cixÿvMv‡ii (Drug Testing Laboratory) kvLv ¯’vc‡bi eë¯’v
Kiv Ges †K›`ªxqfv‡e GKwU ¯^vqËkvwmZ RvZxq †idv‡iÝ cixÿvMvi cÖwZôv
Kiv| BDbvbx, Avqy‡e©w`K, nve©vj I †nvwgIc¨vw_K-ev‡qv‡KwgK Jlamg~‡ni
Rb¨ we‡klvwqZ AvaywbK cixÿvMvi ¯’vcb Kiv|
(L) mÿg M‡elYv ms¯’v wn‡m‡e AvaywbK I UªvwWkbvj Jl‡ai cixÿv, we‡kølY I
†idv‡iÝ cixÿvMv‡ii Kv‡Ri mv‡_ wewmGmAvBAvi (Bangladesh
Council of Scientific and Industrial Research-BCSIR)-†K m¤ú„³
Kiv|
(M) cixÿv I we‡køl‡Yi Rb¨ miKvwi, †emiKvwi I ¯^vqËkvwmZ ch©v‡q cÖwZwôZ
†Kvb M‡elYv cÖwZôvb‡K Third Party Quality Evaluator Gi Av`‡j
¯^xK…wZ †Ìqv|
3.13| †`‡ki Rb¯^v¯’¨ iÿvK‡í A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx, nve©vj I
†nvwgIc¨vw_K Jl‡ai Rb¨ Avjv`v Avjv`v AZ¨vek¨Kxq Jl‡ai ZvwjKv cÖYqb
Kiv|
3.14| Jl‡ai †hŠw³K eënvi wbwðZ Kivi j‡ÿ¨ †iwR÷vW© wPwKrm‡Ki eë¯’vcÎ Qvov
Jla weµq I weZiY wbwl× Kiv|
3.15| DbœZ †`kmg~‡ni Av`‡j mvaviYfv‡e eënv‡ii †ÿ‡Î eë¯’vcÎ-wenxb wbivc`

Jl‡ai (Over-the-Counter-OTC) ZvwjKv cÖKvk Kiv|
3.16| Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jl‡ai gvb Dbœq‡bi
j‡ÿ¨ G¸‡jvi Drcv`b eë¯’vq êÁvwbK cÖhyw³-wbf©i gvb-wbqš¿Y eë¯’v AšÍfz©³
Kiv|
3.17| Jlwa¸Ym¤úbœ, dvg©vwmDwUK¨vj †Wv‡Rm& d‡g© Drcvw`Z I †ivM wbivg‡q wb‡`©kK…Z
cY¨‡K Jla wn‡m‡e MY¨ Kiv Ges G j‡ÿ¨ cÖ‡qvRbxq wbqš¿Y wbwðZ Kiv| †h
mKj cÖmvabx-RvZxq cY¨ kvixwiK †Kvb Kvh©µ‡gi cwieZ©b K‡i _v‡K,
†m¸‡jv‡K Jla cªkvmb Awa`ß‡ii wbqš¿‡Y Avbv|
3.18| †gwWK¨vj wWfvBm I mvwR©K¨vj BKzBc‡g›U hv gvbe kix‡ii ms¯ú‡k© Av‡m,
†m¸‡jv‡K Jla cÖkvmb Awa`ß‡ii wbqš¿‡Y Avbv|
3.19| miKvwi I †emiKvwi ch©v‡q mswkøó †ckvi `ÿ I cÖwkwÿZ Rbe‡ji gva¨‡g
Jl‡ai wK¬wbK¨vj Uªvqvj (Clinical Trial) I ev‡qvBKzf¨v‡jÝ cixÿY
(Bioequivalence Study) myweav m„wó Kiv|
3.20| WTO/TRIPS Pzw³i Av‡jv‡K evsjv‡`‡ki Jla wkí weKv‡k mnvqZv Kiv|
3.21| Jl‡ai cvkvcvwk wewfbœ ai‡bi Lv`¨ mvgMÖxi ¸Yv¸Y I wbivcËv wbwðZK‡í
eZ©gvb ÔJla cÖkvmb Awa`ßiÕ‡K (Directorate General of Drug
Administration) ÔLv`¨ I Jla cÖkvmb Awa`ßiÕ (Directorate General of
Food and Drug Administration)-G iƒcvšÍi Kiv Ges Gme mvgMÖxi Ici
AvBwb wbqš¿Y cÖwZôvi j‡ÿ¨ Gi Kg©cwiwa I mvsMVwbK KvVv‡gv cybwe©b¨vm Kiv|
4| RvZxq Jla bxwZi AvIZvfz³ welqvw`
4.1| we`¨gvb AvBb I wewagvjvi cª‡qvM Ges ms‡kvab
(K) eZ©gv‡b †`‡k wewfbœ c×wZi Jla Drcv`b, gvb-wbqš¿Y, weµq, weZiY,
msiÿY, Avg`vwb, ißvwb wbqš¿Y Ges bRi`vixi †ÿ‡Î we`¨gvb †ek wKQz
bxwZ, AvBb I mswkøó wewagvjv AcÖZzj I m½wZnxb n‡q c‡o‡Q| cwiewZ©Z
†cÖÿvc‡U we`¨gvb Gme AvBb I wewagvjv‡K hy‡Mvc‡hvMx I Kvh©Ki Ki‡Z
G¸‡jv cÖ‡qvRbgZ ms‡kvab Kiv Avek¨K|
(L) Jl‡ai cÖPwjZ AvBbmg~n AviI hy‡Mvc‡hvMx Kivi j‡ÿ¨ Jla AvBb,
1940 (Drug Act, 1940) Ges Jla (wbqš¿Y) Aa¨v‡`k 1982 [Drug
(Control) Ordinance 1982] mgš^‡q evsjvq hy‡Mvc‡hvMx nvjbvMv`K…Z
GKwU AvBb Ges DwjøwLZ AvBbmg~n ev¯Íevq‡bi j‡ÿ¨ cÖ‡qvRbxq WªvM
iæjmg~n (Drug Rules) h_vkxNª cÖYqb Kiv n‡e|
(M) ZvQvov, Lv‡`¨ bKj-†fRvj-wb¤œgvb cÖwZ‡iva K‡i Rb¯^v¯’¨ iÿvi RbÏ
AcÖZzj AvB‡bi welqwU we‡ePbv K‡i Lv`¨ I Jla cÖkvmb Awa`ß‡ii Rb¨
cÖ‡qvRbxq AvBb ˆZwi Kiv n‡e|
(N) †`‡k myôz, Kvh©Ki I Revew`wng~jK Jla eë¯’vcbv wbwðZKi‡Y Ges G
wel‡q †fv³vi AwaKvi cÖwZôv we`¨gvb AvB‡bi weavbmg~n h_vh_ cÖ‡qvM
wbwðZ Kiv n‡e|
4.2| Kvh©Ki, wbivc` I gvbm¤úbœ Jl‡ai mnRjf¨Zv
(K) †`‡k myôz Ges Kvh©Ki ¯^v¯’¨‡mev wbwðZ Kivi j‡ÿ¨ RbM‡Yi cÖ‡qvRb
Abyhvqx Jl‡ai wbivcËv I Dc‡hvwMZv Ges µqÿgZvi w`K we‡ePbv K‡i
miKvi me©¯Í‡i AZ¨vek¨Kxq Jlamn mKj Jl‡ai mnRcÖvc¨Zv wbwðZ
Ki‡e|
(L) g¨v‡jwiqv, KvjvR¡i, wbcvn& (Nipha) fvBivm, mvm© (SARS), h²v, GBWm&
(AIDS) I †W½ymn Ab¨vb¨ msµvgK e¨vwa cÖwZ‡iva I wbg~©jKi‡Yi j‡ÿ¨
mswkøó Jl‡ai mnRjf¨Zv wbwðZ Kiv n‡e|
(M) wkï I gvZ…¯^v‡¯’ï Dbœqb Ges †ivM cÖwZ‡iv‡a wewfbœ cÖKvi gvbm¤úbœ
f¨vKwmb I mswkøó Jl‡ai mnRjf¨Zv Ges cÖvwY¯^v‡¯’ï Dbœqb I †ivM
cÖwZ‡iv‡ai gvbm¤úbœ cÖ‡qvRbxq f¨vKwmb I Jl‡ai mnRjf¨Zv wbwðZ Kiv
n‡e|
4.3| Jl‡ai †hŠw³K I wbivc` eënvi
(K) ÔcÖwgZ wPwKrmv wb‡`©wkKvÕ (Standard Treatment Guideline-STG)
Abyhvqx Jl‡ai †hŠw³K I wbivc` eënvi wbwðZ Kiv n‡e|
(L) 100 ev Zvi †ewk kh¨vwewkó †`‡ki me miKvwi I †emiKvwi nvmcvZv‡j
Gw›Uev‡qvwU‡Ki h_vh_ eënvi wbwðZ Kivi j‡ÿ¨ wbR¯^ ÔGw›Uev‡qvwUK
eënvi wb‡`©wkKvÕ _vK‡Z n‡e, Zv wbqwgZ nvjbvMv` Ki‡Z n‡e Ges
wPwKrmv †mev cÖ`vbKv‡j Zv AbymiY Ki‡Z n‡e| cieZx©‡Z ch©vqµ‡g mKj
nvmcvZv‡ji Rb¨B ÔGw›Uev‡qvwUK eënvi wb‡`©wkKvÕ cÖYqb I Abymi‡Yi
eë¯’v MÖnY Kiv n‡e|
(M) Jla msµvšÍ Z_¨vw` AewnZKiY Ges †hŠw³K eënvi wbwðZK‡í Jla
wbqš¿Y KZ…©c‡ÿi Aby‡gv`b mv‡c‡ÿ Ôevsjv‡`k b¨vkbvj dgy©jvwiÕ ev
wewWGbGd (Bangladesh National Formulary-BDNF) wbqwgZfv‡e
nvjbvMv` I I‡qe mvB‡U cÖKvk Kiv n‡e| GKBfv‡e Jla wbqš¿Y
KZ…©c‡ÿi Aby‡gv`b mv‡c‡ÿ Ôevsjv‡`k RvZxq Avqy‡e©w`K dgy©jvwiÕ,
Ôevsjv‡`k RvZxq BDbvbx dgy©jvwiÕ, Ôevsjv‡`k RvZxq nve©vj dgy©jvwiÕ Ges
Ôevsjv‡`k †nvwgIc¨vw_K dvg©v‡KvwcqvÕ wbqwgZ cÖYqb, nvjbvMv` I I‡qe
mvB‡U cÖKvk Kiv n‡e|
(N) †ivMx‡K Jl‡ai h_v_© eënviwewa I msiÿ‡Yi wel‡q civgk© cÖ`v‡bi Rb¨
Jla wewµ A_ev cwi‡ekb (Dispensing) Kvh©µg †ckvRxex dvg©vwm÷‡ì
cÖZ¨ÿ ZË¡veav‡b cwiPvwjZ n‡e| G j‡ÿ¨ KwgDwbwU dv‡g©mx (Community
Pharmacy) cÖwZôv I Dbœq‡b cÖ‡qvRbxq eë¯’v MÖnY Kiv n‡e|
(O) †`‡k ch©vqµ‡g me miKvwi I †emiKvwi nvmcvZv‡j ¯œvZK dvg©vwm÷ Gi
cÖZ¨ÿ ZË¡veav‡b ÔnmwcUvj dv‡g©mxÕ (Hospital Pharmacy) Kvh©µg
cwiPvjbvi cÖ‡qvRbxq eë¯’v MÖnY Kiv n‡e| Jl‡ai †hŠw³K eënvi wbwðZ
Kivi j‡ÿ¨ cÖwZwU nvmcvZv‡ji wbR¯^ Jla wb‡`©wkKv (dgy©jvix) cÖYqb,
wbqwgZ nvjbvMv` I I‡qe mvB‡U cÖKvk Kiv n‡e|
(P) mKj ¯^xK…Z c×wZi Jl‡ai cwiPq mevi Kv‡Q mnR Kivi j‡ÿ¨ evwYwR¨K
bv‡gi cvkvcvwk ¯úófv‡e †R‡bwiK ev wbR wbR dgy©jvwi‡Z DwjøwLZ bv‡g
Jla Drcv`b/wecYb Ki‡Z n‡e| miKvwi mKj ch©v‡q †R‡bwiK bv‡g Jla
mieivn I eënvi‡K DrmvwnZ Kiv n‡e|
(Q) †iwR÷vW© wPwKrmK/†f‡Uwibvwiqvb Gi eë¯’vcÎ e¨wZ‡i‡K Over the
Counter (OTC) Jla e¨ZxZ Ab¨ †Kvb Jla LyPiv weµq Kiv hv‡e bv|
(R) Jl‡ai †hŠw³K eënvi g~j¨vqb Kivi j‡ÿ¨ wbqwgZfv‡e wbw`©ó mgq AšÍi
Jl‡ai eë¯’vcÎ Ges cwi‡ekb (Dispensing) c×wZ ch©‡eÿY (Monitor)
Kiv n‡e|
(S) Gw›Uev‡qvwUKmn me ai‡bi Jl‡ai †hŠw³K eënvi wbwðZ Kivi j‡ÿ¨
†`‡ki mKj miKvwi I †emiKvwi nvmcvZv‡j ÒWªvMm GÛ †_ivwcDwUK
KwgwUÓ cÖwZôv Kiv n‡e|
(T) AZ¨vek¨Kxq Jl‡ai K‡ÝÞ Gi Dci wfwË K‡i wbqwgZfv‡e AZ¨vek¨Kxq
Jl‡ai ZvwjKv (EML) nvjbvMv` Kiv n‡e|
4.4| Jl‡ai wbeÜb
(K) wbeÜ‡bi Rb¨ Jla wbe©vPb
1| mKj Jla hv †`‡k wewfbœ †Wv‡Rm d‡g© Drcv`b, Avg`vwb, weZiY I
wecYb ev eënvi nq Zv Aek¨B Jla wbqš¿Y KwgwUi (Drug
Control Committee-DCC) mycvwi‡ki wfwË‡Z WªvM jvB‡mwÝs
KZ…©cÿ Øviv wbewÜZ n‡Z n‡e| Rxeb iÿvKvix bZzb Jla RbM‡Yi
Rb¨ `ªæZ mnRjf¨ Kivi D‡Ï‡k¨ wbqwgZ Jla wbqš¿Y KwgwUi mfv
AbywôZ n‡e|
2| Jla wbqš¿Y KwgwUi KvR n‡e ¯’vbxqfv‡e Drcv`b A_ev Avg`vwbi
wbwg‡Ë Av‡ew`Z mKj Jla I †gwW‡Kj wWfvBm-Gi wbivcËv,
Kvh©KvwiZv Ges Dc‡hvwMZv (Safety, efficacy and usefulness)
g~j¨vq‡bi gva¨‡g wbeÜ‡bi Rb¨ gZvgZ ev mycvwik cª`vb Kiv| G
D‡Ï‡k¨ mswkøó we‡klÁ I †ckvRxexi mgš^‡q Jla wbqš¿Y KwgwU
MwVZ n‡e|
(L) wbeÜ‡bi gvb`Ð
1| cÖwZwôZ wb‡`©kbv Abyhvqx Jl‡ai wbeÜb cÖ`vb Kiv n‡e| Jla
wbqš¿Y KwgwUi mycvwik e¨wZ‡i‡K †Kvb Jl‡ai bZzb wb‡`©kbv
Aby‡gv`b Kiv hv‡e bv|
2| cÖ‡qvRbxq AeKvVv‡gv Ges gvb wbwðZKiY eë¯’v (Quality
Assurance Management) e¨ZxZ †Kvb cªwZôvb‡K Jla
Drcv`‡bi AbygwZ †Ìqv n‡e bv| D”P cÖhyw³i †Kv‡bv Jla ev m¤ú~Y©
Avjv`v KvVv‡gv I my‡hvM-myweavwì (Dedicated) cÖ‡qvRb nq Ggb
Jla wek¦ ¯^v¯’¨ ms¯’vi wRGgwc MvBW jvBb Abyhvqx Drcv`‡bi
cª‡qvRbxq KvVv‡gv e¨ZxZ wbeÜb †Ìqv n‡e bv| D‡jøL¨ †h,
B‡Zvg‡a¨ †hme Jla wbeÜb †Ìqv n‡q‡Q Zv cybtg~j¨vqbc~e©K
ïaygvÎ †hvM¨Zvm¤úbœ cÖwZôvb‡K Drcv`‡bi AbygwZ †Ìqv n‡e|
3| wPwKrmvq AZ¨vek¨Kxq cÖZxqgvb bv n‡j wgkÖYRvZxq
(Combination) A¨v‡jvc¨vw_K Jl‡ai wbeÜb mvaviYfv‡e
wbiærmvwnZ Kiv n‡e| mswkøó Combination Product Gi †ÿ‡Î
Aceënv‡ii m¤¢vebv ¸iæ‡Z¡i mv‡_ we‡ePbvq ivL‡Z n‡e|
A¨v‡jvc¨vw_K Jl‡ai †iwR‡÷ªkb cÖ`v‡bi †ÿ‡Î United States
Food & Drug Administration (US-FDA) ev The Medicines
& Healthcare Products Regulatory Agency (MHRA) KZ…©K
Aby‡gv`‡bi ev British National Formulary (BNF) G AšÍf©yw³i
Z_¨vw` AbymiY Ki‡Z n‡e| cÖPwjZ Combination Product-mg~‡ni
wbeÜb cÖ‡qvRb Abyhvqx cybg©~j¨vqb Kiv n‡e|
4| BDbvbx, Avqy‡e©w`K, nvev©j I †nvwgIc¨vw_K-ev‡qv‡KwgK Jlamg~n
Jla wbqš¿Y KwgwUi mycvwi‡ki wfwË‡Z WªvM jvB‡mwÝs KZ…©cÿ Øviv
wbewÜZ n‡Z n‡e| †KejgvÎ BDbvbx, Avqy‡e©w`K I †nvwgIc¨vw_K
dg©yjvwi/dvg©v‡Kvwcqvi AšÍf©y³ Jlamg~‡ni wbeÜb we‡ePbv Kiv
n‡e|
5| gv`viwUsPvi, A‡kvwaZ UªvBUz¨‡ikb I 12wU ev‡qv‡Kwg Jl‡ai 1×
c‡UÝxi Rb¨ wbeÜ‡bi cÖ‡qvRb n‡e, wKš‘ †nvwgIc¨vw_K I ev‡qv‡Kwg
Jlamg~‡ni c‡UÝx AviI e„w×i Rb¨ †Kvb wbeÜ‡bi cÖ‡qvRb n‡e bv|
6| †nvwgIc¨vw_K dvg©v‡Kvwcqv Abyhvqx Zij Jla KwVb evnK, h_v-
j¨vK‡UvR/ †MøvweDjm BZ¨vw` Ges KwVb Jla Zij evnK, h_v-
weï× cvwb/A¨vj‡Kvnj BZ¨vw` mn‡hv‡M mswgkÖY/iƒcvšÍi K‡i
†meb‡hvM¨| G‡ÿ‡Î Zij n‡Z KwVb AvKvi (dg©) ev KwVb n‡Z
Zij AvKv‡i iƒcvšÍ‡ii gva¨‡g kw³K…Z Jl‡ai wbeÜ‡bi cÖ‡qvRb
n‡e bv|
(M) Avg`vbxi Rb¨ wbeÜb

1| we‡`‡k Drcvw`Z I evsjv‡`‡k wbewÜZ Jla, jvB‡mwÝs KZ…©c‡ÿi
AbygwZ mv‡c‡ÿ Avg`vwb Kiv hv‡e| Avg`vwbK…Z Jl‡ai
†iwR‡÷ªk‡bi Rb¨ Bioequivalence Study I Clinical Trial
msµvšÍ Z_¨vw` `vwLj Ki‡Z n‡e| Avg`vwbi Rb¨ wbeÜ‡bi †ÿ‡Î
be-Avwe®‹„Z Rxeb iÿvKvix Jlamg~n‡K AMÖvwaKvi cÖ`vb Kiv n‡e|
mswkøó Jla GKB cY¨bv‡g wb¤œewY©Z Kgc‡ÿ GKwU DbœZ †`‡k

evRviRvZKi‡Yi Rb¨ wbewÜZ n‡Z n‡e : hy³ivóª, hy³ivR¨, Rvg©vwb,
d«vÝ, myBRvij¨vÛ, Rvcvb I A‡÷ªwjqv| Z‡e D³ Avg`vbx‡hvM¨ Jla
Avwe®‹viK †Kv¤úvbxi g~j Drcv`b KviLvbv (Original
Manufacturing Site) A_ev DcwiD³ †h †Kvb GKwU †`‡k Aew¯’Z
Drcv`b KviLvbv †_‡K msM„nxZ n‡Z n‡e|
2| cÖvwYm¤ú` I grm¨ wPwKrmvi Jl‡ai Avg`vwb †iwR‡÷ªk‡bi †ÿ‡Î
D³ Jla evRviRvZKi‡Yi D‡Ï‡k¨ Drm †`k Ges BD‡ivcxq
BDwbqbfz³ †`k Ges hy³ivóª, myBRvij¨vÛ, KvbvWv, A‡÷ªwjqv,
Rvcvb, `wÿY †Kvwiqv I wm½vcyi Gi AšÍZt GKwU †`‡ki wd« †mj
mvwU©wd‡KU (Free Sale Certificate) `vwLj Ki‡Z n‡e| D‡jøL¨ †h,
D³ Jla ZvwjKvfz³ †`k ev †`kmg~‡n GKB eªvÛ bv‡g weµ‡qi Rb¨
wbewÜZ _vK‡Z n‡e|
3| Avg`vwbK…Z Jla I KuvPvgvjmg~n h_vh_fv‡e wRGgwc Abymi‡Y
Drcvw`Z nq wKbv †m wel‡q wbwðZ nIqvi j‡ÿ¨ cÖZ¨qbcÎ `vwL‡ji
eë¯’vmn cÖ‡qvRb‡ev‡a RvZxq Jla wbqš¿YKvix KZ…©c‡ÿi cÿ †_‡K
Drcv`bKvix cÖwZôvb cwi`k©b Kiv n‡e| GMP MvBWjvBb Ges
cÖYxZ Check List Gi Av‡jv‡K ißvwbKviK †`‡ki Jla KviLvbv
Validation Certification Kiv n‡e|
4| nvev©j I †nvwgIc¨vw_K-ev‡qv‡KwgK Jlamg~n Jla wbqš¿Y KwgwUi
mycvwi‡ki wfwË‡Z Jla cÖkvmb Awa`ßi KZ…©K Avg`vwbi D‡Ï‡k¨
wbewÜZ n‡Z n‡e| †`kxq †flR n‡Z D™¢~Z nIqvq BDbvbx I
Avqy‡e©w`K Jla Avg`vbxi Rb¨ we‡ePbv Kiv n‡e bv, Z‡e BDbvbx I
Avqy‡e©w`K Jl‡ai g‡a¨ †h mKj AZ¨vek¨Kxq Jla hv †`‡k-
Drcvw`Z nq bv †m¸‡jv Avg`vbxi my‡hvM ivLv †h‡Z cv‡i|
5| ÁvZ ¸iæZi cvk¦© cÖwZwµqv nIqvi m¤¢vebv _vKv m‡Ë¡I weKí Jla bv
cvIqv †M‡j wbw`©ó wKQz Jla wbqwš¿Z eënv‡ii D‡Ï‡k¨ mxwgZ
cwigv‡Y Avg`vwbi Aby‡gv`b †Ìqv †h‡Z cv‡i|
4.5 Jla I Jl‡ai KuvPvgv‡ji Drcv`b

(K) RvZxq JlabxwZi Ab¨Zg cÖavb jÿ¨ n‡”Q ch©vß cwigv‡Y gvbm¤úbœ
Jla Drcv`b| AZGe, †`‡k Jla Drcv`‡bi †ÿ‡Î wek¦ ¯^v¯’¨
ms¯’vi current Good Manufacturing Practices(cGMP)
wb‡`©kbvmg~n K‡Vvifv‡e AbymiY Kiv n‡e|
(L) cÖ¯‘ZKviKMY Jla cÖkvmb Awa`ß‡ii cÖYxZ †PK wj÷ (Check
list) AbymiY K‡i wbw`©ó mgq AšÍi Af¨šÍixY wbixÿv (Internal
Audit) cwiPvjbv Ki‡eb| Jla cÖkvmb Awa`ßi, cÖYxZ †PKwj÷
wbqwgZ nvjbvMv` Ki‡e|
(M) Jl‡ai Drcv`‡bi wewfbœ kZ© †hgb †Kv¤úvbxi †hvM¨ Rbej, ¯’vcbv/
†cÖwg‡mm, BDwUwjwU/mvwf©‡mm, ¯’vwcZ †gwkbvwi/BKzBc‡g›U, Drcvw`Z
Jl‡ai †_ivwcDwUK †kÖYx Ges †Wv‡Rm dg© BZ¨vw` we‡ePbv K‡i
Zv‡ì‡K Jla Drcv`‡bi mvg_©¨ Abyhvqx †kÖYxweb¨vm Kiv n‡e|
(N) Jl‡ai KuvPvgvj Drcv`‡bi Rb¨ Avgw`bK…Z †KwgK¨v‡ji Ici
g~mK/Ki gIKz‡di wel‡q Af¨šÍixY m¤ú` wefvM Z_v RvZxq ivR¯^
†ev‡W©i m‡½ Av‡jvPbvµ‡g †hŠw³K ch©v‡q n«vmmn wewfbœ cÖ‡Yv`bvi
D‡`¨vM †bIqv n‡e| G j‡ÿ¨ Jl‡ai KuvPvgv‡ji Dci M‡elYvq
wb‡qvwRZ cÖwZôvbmg~n‡K DrmvwnZ Kiv n‡e Ges cÖ‡qvRbxq cÖ‡Yv`bv
†Ìqv n‡e| KuvPvgvj Drcv`‡bi Rb¨ Bmy¨K…Z jvB‡m‡Ýi AvIZvq
wdwbm&W WªvM Drcv`b Kiv hv‡e bv|
(O) Jlawk‡í ¯^qsm¤ú~Y©Zv AR©‡bi Rb¨ mKj ¯^xK…Z c×wZi Jl‡ai
KuvPvgv‡ji Dci we‡`k wbf©iZv n«vm Kiv n‡e| Jl‡ai KuvPvgvj
Drcv`‡bi Rb¨ wkí ¯’vcb, Pzw³wfwËK Drcv`b, we‡`kx †Kv¤úvbxi
mv‡_ Under License-wfwËK Drcv`b Ges †`kx-we‡`kx †hŠ_
wewb‡qvM‡K wewfbœ ch©v‡q cÖ‡Yv`bv †Ìqvi D‡`¨vM MÖnY Kiv n‡e|
GKBfv‡e †`kxq c¨v‡KwRs wkí weKv‡k Drmvn †Ìqv n‡e|
(P) †`‡k Drcvw`Z Jl‡a eëüZ KvuPvgvj mswkøó dvg©v‡Kvwcqvq DwjøwLZ
†¯úwmwd‡Kkb Abyhvqx gvbm¤úbœ n‡Z n‡e|
(Q) evsjv‡`‡k A¨v‡jvc¨vw_K Jla Drcv`b KviLvbv i‡q‡Q Ggb
cÖwZôvb‡K gvïj cÖ`vb eë¯’vax‡b (Toll Manufacturing) Zv‡ì
cQ›`g‡Zv evsjv‡`‡ki Ab¨ †h †Kv‡bv A¨v‡jvc¨vw_K Jla Drcv`b
KviLvbvq Jla Drcv`‡bi AbygwZ †Ìqv hv‡e|
(R) evsjv‡`‡k Jla Drcv`b KviLvbv †bB Ggb we‡`kx †Kv¤úvbx ïaygvÎ
ißvwbi D‡Ï‡k¨ me ¯^xK…Z c×wZi Jla ¯^ ¯^ c×wZi †Kv¤úvbxi mv‡_
Pzw³wfwËK/ †jvb jvB‡m‡Ýi AvIZvq (Contract Manufacturing/
Loan License) Drcv`b Ki‡Z cvi‡e| Drcvw`Z D³ Jla
†Kvbfv‡eB ¯’vbxq evRv‡i evRviRvZ Kiv hv‡e bv|
(S) cÖhyw³ n¯ÍvšÍi A_ev be-D™¢vweZ Jlamg~‡ni jf¨Zv wbwðZ Kivi

j‡ÿ¨ evsjv‡`‡k Drcv`b BDwbU bvB Ggb we‡`kx †Kv¤úvbx‡K Zvi
wbR¯^ M‡elYvjä Jla Zvi cQ›` Abyhvqx †`kxq †Kvb †Kv¤úvbxi
ms‡M jvB‡mÝ cÖ`vb Pzw³i AvIZvq ¯’vbxqfv‡e Drcv`‡bi AbygwZ
cÖ`vb Kiv n‡e hw` D³ Jla GKB cY¨ bv‡g Kgc‡ÿ wb¤œewY©Z
GKwU DbœZ †`‡k evRviRv‡Zi D‡Ï‡k¨ wbewÜZ _v‡K : hy³ivóª,
hy³ivR¨, myBRvij¨vÛ, Rvg©vbx, d«vÝ, Rvcvb I A‡÷ªwjqv|
(T) Jla cÖkvmb Awa`ß‡ii c~e©vby‡gv`b mv‡c‡ÿ †Kvb Jl‡ai D”P
cÖhyw³m¤úbœ cixÿv I we‡køl‡Yi Rb¨ cÖ‡qvRbxq gvïj cÖ`vb
eë¯’vax‡b (Contract Analysis) †Kvb cÖwZôvb Zv‡ì cQ›`g‡Zv
Jla cÖkvmb KZ…©K ¯^xK…Z †Kvb miKvwi, †emiKvwi I ¯^vqËkvwmZ
cÖwZôvb hv‡ì G msµvšÍ cixÿv I we‡kølY myweav i‡q‡Q Zv‡ì‡K
¯^xK…wZ †Ìqv n‡e| G wel‡q Jla cÖkvmb Awa`ßi cÖ‡qvRbxq
MvBWjvBb cÖYqb Ki‡e|
(U) Jla Drcv`‡b ¯^í cwigv‡Y eëüZ KuvPvgvj I †idv‡iÝ ÷¨vÛvW©
Drcv`bKvix cÖwZôvbmg~n †hŠ_fv‡e Jla cÖkvmb Awa`ß‡ii
Aby‡gv`bµ‡g Avgvw`b Ki‡Z cvi‡e| G †ÿ‡Î Avg`vwbKviKMY
GMP Compliance wbwðZ Ki‡eb|
(V) †`‡ki Riæix cÖ‡qvR‡b ev Rb¯^v¯’¨ iÿvq †h †Kvb Jla cÖ¯‘ZKvix‡K
miKvi †h †Kvb Jla Drcv`‡bi wb‡`©k w`‡Z cvi‡e Ges
cÖwZôvb¸‡jv Zv Drcv`‡b eva¨ _vK‡e|
(W) Ggb me we‡`kx I eûRvwZK †Kv¤úvbx¸‡jv‡K evsjv‡`‡k KviLvbv
¯’vcb I Jla cÖ¯‘Z Kivi AbygwZ †Ìqv n‡e hv‡ì Kgc‡ÿ wZbwU
g~j M‡elYvjä Jla wb‡¤œ ewY©Z †`k¸‡jvi g‡a¨ Kgc‡ÿ `yÕwU †`‡k
wbewÜZ _vK‡e : hy³ivóª, hy³ivR¨, myBRvij¨vÛ, Rvg©vbx, d«vÝ, Rvcvb
I A‡÷ªwjqv|
(X) †hme A¨v‡jvc¨vw_K Jla weªwUk dvg©v‡Kvwcqv (BP), BDbvB‡UW
†÷Um dvg©v‡Kvwcqv (USP), BD‡ivwcqvb dvg©v‡Kvwcqv (EP),
B›Uvib¨vkbvj dvg©v‡Kvwcqv (IP) A_ev weªwUk dvg©vwmDwUK¨vj
†Kv‡W· (BPC)-Gi c~e©eZ©x wZbwU ms¯‹i‡Yi †h‡Kvb GKwU‡Z A_ev
wek¦ ¯^v¯’¨ ms¯’vi B›Uvib¨vkbvj bb-†cÖvcvBUix †bgm& (INN) Gi
ZvwjKvfz³ bq †mme Jla Drcv`‡bi AbygwZ †Ìqv n‡e bv|
(Y) Jla KviLvbvmg~‡n h_vh_fv‡e Jl‡ai gvb wbwðZKi‡Yi j‡ÿ¨
mswkøó Rbe‡ji Rb¨ cÖwZôvb wbqwgZ cGMP welqK cÖwkÿ‡Yi
eë¯’v Ki‡e|
(Z) `ÿZv e„w×i Rb¨ Jla cÖkvmb Awa`ß‡ii cwi`k©K‡ì wbqwgZ

wRGgwc I Ab¨vb¨ cÖvmw½K wel‡q cÖwkÿY cÖ`vb Kiv n‡e| †`‡k I
we‡`‡k DwjøwLZ cÖwkÿ‡Yi Rb¨ cÖ‡qvRbxq D‡`¨vM MÖnY Kiv n‡e Ges
cÖwkÿY msµvšÍ Znwe‡ji eë¯’v Kiv n‡e|
4.6 RvZxq Jla wbqš¿Kvix KZ…©cÿ (National Regulatory Authority-NRA)

(K) Jla cÖkvmb Awa`ßi‡K AwaKZi kw³kvjx Jla wbqš¿Kvix ms¯’v
wn‡m‡e M‡o †Zvjv AZ¨ve¨kK| Jla wbqš¿Y KZ…©cÿ wn‡m‡e hveZxq
Kvh©vejx h_vh_fv‡e m¤úv`‡bi Rb¨ †ckvMZfv‡e wkwÿZ I AwfÁ
cÖ‡qvRbxq msL¨K Rbej wb‡qvM †Ìqv n‡e| Jl‡ai wbeÜb,
cÖ¯ÍZKiY, msiÿY, weZiY, weµq, Avg`vwb, ißvwb I gvb m¤úwK©Z
wel‡q wb‡qvwRZ Rbe‡ji `ÿZv/mÿgZv (Competence) e„w×i
j‡ÿ¨ wbqwgZ cÖwkÿY cÖ`vb Kiv n‡e| †f‡Uwibvwi WªvM‡mi †ÿ‡ÎI
DwjøwLZ wel‡q wb‡qvwRZ Rbe‡ji `ÿZv e„w×i j‡ÿ¨ †f‡Uwibvwi
we‡klÁ‡ì Øviv wbqwgZ cÖwkÿY cÖ`vb Kiv n‡e|
(L) Jla cÖkvmb Awa`ß‡ii wb‡qvwRZ Rbe‡ji Rb¨ GKwU Kvh©Ki gvbe
m¤ú` Dbœqb Kg©m~Px MÖnY Kiv n‡e Ges †mB mv‡_ Kg©iZ Rbe‡ji
`ÿZv, AwfÁZv I cvidi‡g‡Ýi wfwË‡Z wbqwgZ c‡`vbœwZmn K¨vwiqvi
†W‡fjc‡g›U cø¨vb (Career Development Plan) wbwðZ Kiv n‡e|
(M) Jla cÖkvmb Awa`ßi‡K WHO-Gi Accreditated Ges PIC/S-Gi

m`m¨fz³ nIqvi Rb¨ kZ©vewj c~iY Kivi cÖ‡qvRbxq eë¯’v MÖnY Kiv
n‡e|
(N) RvZxq Jla wbqš¿YKvix KZ…©c‡ÿi AvBbMZ welqvw` Kvh©Kifv‡e

cwiPvjbvi j‡ÿ Awa`ß‡i Dchy³ Rbejmn GKwU wjM¨vj †mj
(Legal Cell) MVb Kiv n‡e| bKj †fRvj I wb¤œgv‡bi Jl‡ai
Drcv`b, weZiY, gRy` I wewµi weiæ‡× `ªæZ AvBbMZ eë¯’v
†bIqvi j‡ÿ Awa`ß‡i wePvwiK ev wbe©vnx g¨v‡R‡÷ªU wb‡qv‡Mi eë¯’v
MÖnY Kiv n‡e|
(O) RvZxq Jla wbqš¿YKvix KZ…©c‡ÿi I‡qemvBU wbqwgZfv‡e nvjbvMv`

Kiv n‡e Ges Awa`ß‡ii cÖvmw½K Z_¨vw`, c×wZ I M„nxZ eë¯’vw`
mwbœ‡ewkZ n‡e| MwZkxjZv e„w×i j‡ÿ ch©vqµ‡g Awa`ß‡ii wewfbœ
Kvh©µg Ab-jvB‡b (On-line) cwiPvjbvi eë¯’v †bIqv n‡e|
4.7 bKj, †fRvj I wb¤œgv‡bi Jla cÖ¯‘Z, weµq I weZiY †iva

(K) bKj, †fRvj, †gqv‡`vËxY©, wbeÜbwenxb, KvD›Uvi‡dBU I wgmeªv‡ÛW
Jla wewµ kvw¯Í‡hvM¨ Aciva Ges Jla eë¯’vcbvq mykvm‡bi
AšÍivq weavq Drcv`K I Avg`vbxKviK cÖwZôvb, cvBKvix I LyPiv
we‡µZv G wel‡q `vqe×| Giƒc Jl‡ai Drcv`b, wecYb, weµq,
weZiY I gRy‡ì mv‡_ mswkøó e¨w³ I cÖwZôv‡bi weiæ‡× AvBbvbyM
K‡Vvi eë¯’v MÖnYmn Jla cÖkvmb Awa`ßi KZ…©K msw&køó jvB‡mÝ
evwZj Kiv n‡e|
(L) wb¤œgvb, bKj, †fRvj I wbeÜbwenxb Jla (A¨v‡jvc¨vw_K,
Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK) Ges dzW
mvwcø‡g‡›Ui bv‡g JlaRvZxq c‡Yï Abby‡gvw`Z Drcv`K I we‡µZv,
eë¯’vcÎ cÖ`vbKvix wPwKrmK I wPwKrmv-cÖwZôv‡bi Rb¨ `„óvšÍg~jK
kvw¯Í cÖ`vb wbwðZ Ki‡Z we`¨gvb AvB‡bi ms¯‹vi Kiv n‡e|
(M) †gqv` DËxY© Jla dv‡g©mx‡Z gIRy`, cÖ`k©b, Jl‡ai †gvoK ev
avi‡Ki Dci wb‡`©wkZ †gqv` cwieZ©b ev A¯úó K‡i weµq
kvw¯Í‡hvM¨ Aciva wn‡m‡e MY¨ n‡e|
(N) wb¤œgvb, bKj, †fRvj †PvivPvjvbK…Z Lv`¨ ev Jla mvgMÖx eënv‡i
ÿwZMÖ¯Í n‡j †fv³vi Dchy³ ÿwZc~iY wbwðZ Ki‡Z we`¨gvb AvBb
ms‡kvab Kiv n‡e|
4.8 Jla wbe©vPb, cwigvY wba©viY, Jla msMÖn, gRy`KiY I weZiY c×wZ
(K) msKU I `y‡h©vM †gvKv‡ejvq Jla cÖkvmb Awa`ß‡ii gZvgZ MÖnY
mv‡c‡ÿ miKvi Riæix wfwË‡Z AwbewÜZ Jla Avg`vwb A_ev `vb
wn‡m‡e MÖnY Ki‡Z cvi‡e|
(L) †hme Jla wbewÜZ bq †m me Jla †ivMx‡ì e¨w³MZ eënvi A_ev
M‡elYv I wK¬wbK¨vj cixÿvg~jK cÖ‡qv‡Mi Rb¨ mywbw`©ó cwigv‡Y I
AevwYwR¨K D‡Ï‡k¨ jvB‡mÝ cÖ`vbKvix KZ…©c‡ÿi c~e©vbygwZµ‡g
Avg`vwb Kiv hv‡e|
(M) Jla cÖkvmb Awa`ßi KZ…©K AbwZwej‡¤^ Jla weZiY MvBW jvBb
(Good Distribution Practices-GDP) cÖYqb Kiv n‡e| D³ MvBW
jvBb AbymiYc~e©K Jl‡ai cwienb, weZiY I gIRy`KiY eë¯’v
wbwðZ Kiv n‡e|
(N) Jl‡ai h_vh_ msMÖn, msiÿY I weµq/weZiY wbwðZ Kivi j‡ÿ
evsjv‡`k dv‡g©mx KvDwÝ‡ji wbewÜZ dvg©vwm‡÷i ZË¡veav‡b mKj
dv‡g©mx, miKvwi I †emiKvwi Jla msiÿYvMvi Ges nvmcvZvj
dv‡g©mx cwiPvwjZ n‡e|
(O) Avqy‡e©w`K, BDbvbx, nvev©j I †nvwgIc¨vw_K-ev‡qv‡KwgK Jl‡ai

h_vh_ msMÖn, msiÿY, weµq I weZiY wbwðZ Kivi j‡ÿ mswkøó
c×wZi wbewÜZ wPwKrmK A_ev wbewÜZ dvg©vwm‡÷i ZË¡veav‡b
dv‡g©mx cwiPvwjZ n‡e|
4.9 Jl‡ai weÁvcb I cÖPvi wbqš¿Y
(K) Jl‡ai (OTC ZvwjKvfz³ Jlamn) wecY‡b AmZ¨, AhvwPZ I
weåvwšÍKi Z_¨ cÖ`vb †iv‡a Jla cÖkvmb Awa`ßi KZ…©K Aby‡gvw`Z
Ô†KvW Ae dvg©vwmDwUK¨vjm gv‡K©wUs cÖ¨vKwU‡mmÕ AbymiY Kiv n‡e|
Jla Drcv`bKvix I wecYbKvix cÖwZôvmg~n D³ Ô†KvW Ae
dvg©vwmDwUK¨vjm gv‡K©wUs cÖ¨vKwU‡mmÕ Abyhvqx Zv‡ì wecYb Kvh©µg
cwiPvjbv Ki‡e| D³ Ô†KvW Ae dvg©vwmDwUK¨vjm gv‡K©wUs
cÖ¨vKwU‡mmÕ wbqwgZ nvjbvMv` Kiv n‡e|
(L) jvB‡mwÝs KZ…©c‡ÿi c~e©vby‡gv`b Qvov Jl‡ai †Kvb ai‡bi weÁvcb
cÖPvi Kiv hv‡e bv Ges Aby‡gv`bnxb weÁvcb cÖPv‡ii Rb¨ AvBbMZ
eë¯’v †bIqv n‡e| GKB j‡ÿ †h †Kvb A‰bwZK wecYb (Unethical
Marketing) wKsev eû¯Íi wecYb (Multi Level Marketing) †iva
Kiv n‡e|
(M) Jla wbqš¿Y KZ…©c‡ÿi c~e©vby‡gv`b mv‡c‡ÿ Iivj winvB‡Wªkb më,
Rb¥ weiwZKiY Jla I wWfvBR, cvwb weï×KiY Jla, Gw›U‡mcwUK
Jla, m¤úªmvwiZ UxKv`vb Kg©m~Px‡Z eëüZ f¨vKwmb Gi e¯‘wbô,
wkÿvg~jK Ges Rbm‡PZbZvg~jK weÁvcb cÖPvi Kiv hv‡e|
4.10 ¯^”Q I †hŠw³Kfv‡e Jl‡ai g~j¨ wba©viY
(K) miKvi Rb¯^v‡_© we‡ePbv K‡i Jl‡ai g~j¨ wbqš¿Y msµvšÍ bxwZgvjv
wbqwgZ nvjbvMv` Ki‡e|
(L) g~j¨ wba©vi‡Yi †ÿ‡Î miKvi KZ…©K cÖYxZ bxwZgvjv Abyhvqx cÖwZ
erm‡i AšÍZt GKevi Jl‡ai g~j¨ nvjbvMv` Kiv n‡e| RbM‡Yi
AeMwZi Rb¨ mKj Jl‡ai LyPiv g~j¨ Jla cÖkvmb Awa`ß‡ii
I‡qemvBU-G cÖKvk Kiv n‡e|
(M) †`‡k Drcvw`Z I Avg`vwbK…Z Avqy‡e©w`K, BDbvbx, nve©vj I
†nvwgIc¨vw_K-ev‡qv‡KwgK Jl‡ai g~j¨ miKvi KZ…©K wba©vwiZ n‡e|
(N) wba©vwiZ g~‡jï †P‡q AwZwi³ g~‡j¨ Jla weµq Ki‡j mswkøó e¨w³
ev cÖwZôv‡bi weiæ‡× AvBbvbyM eë¯’v †bIqv n‡e|
4.11 †`‡k bZzb cÖhyw³ I KvwiMwi Ávb n¯ÍvšÍi

(K) cÖhyw³ n¯ÍvšÍi I AvšÍR©vwZK gv‡bi `ÿ Rbkw³ ˆZix‡Z
M‡elYvwfwËK †`kx, we‡`kx, miKvwi, †emiKvwi I ¯^vqËkvwmZ
cÖwZôvbmg~‡ni f~wgKv ¸iæZ¡c~Y©| †`‡k bZzb cÖhyw³ I KvwiMwi Ávb
n¯ÍvšÍ‡ii h_vh_ wbðqZvmn be-Avwe®‹…Z Ges D”P cÖhyw³i Jla
†hgb-ev‡qv‡UK‡bvjwRcÖm~Z f¨vKwmb, ev‡qvwmwgjvi, ni‡gvb,
Bbmywjb, G¨vw›UK¨vÝvi BZ¨vw` Jla Drcv`b I evRviRv‡Zi Rb¨
M‡elYvwfwËK we‡`kx Jla cÖ¯‘ZKviMY‡K DrmvwnZ Kiv n‡e|
(L) AvšÍR©vwZK evRv‡i cÖ‡e‡ki kZ© c~i‡Y PIC/s, US-FDA, EMA,
UK-MHRA, Australian-TGA-Gi mb`cÖvß Jla cÖ¯‘ZKvix
cÖwZôvb †`‡k AviI cÖ‡qvRb i‡q‡Q| †mRb¨ M‡elYvwbf©i we‡`kx
Jla cÖ¯‘ZKvi‡Ki mv‡_ evsjv‡`‡ki Jla cÖ¯‘ZKviK cÖwZôv‡bi
†hŠ_ D‡`¨v‡M wkí ¯’vc‡b Drmvn cÖ`vb Kiv n‡e|
4.12 Jla M‡elYv I Dbœq‡b mgwš^Z †hŠ_ D‡`¨vM
(K) ¯’vbxq I eûRvwZK Jla I Jl‡ai KuvPvgvj cÖ¯‘ZKviK Dfq‡KB
†`‡k M‡elYv I Dbœqb (Research and Development-R&D)
myweav ¯’vcb Kivi Rb¨ Drmvn cÖ`vb Kiv n‡e| G mKj M‡elYvMv‡ii
Rb¨ Avg`vwbK…Z hš¿cvwZi Dci Av‡ivwcZ ïénvi Kgv‡bvi D‡`¨vM
†bIqv n‡e| Jla msµvšÍ †gŠwjK I dwjZ M‡elYv Kvh©µg MÖn‡Yi
Rb¨ wek¦we`¨vjq, M‡elYv Bbw÷wUDU I cÖ¯‘ZKviK‡ì g‡a¨
mn‡hvwMZvi †ÿÎ ˆZwi KiZ: †hŠ_ M‡elYv‡K DrmvwnZ Kiv n‡e|
(L) me ¯^xK…Z dv‡g©mx welqK †Kv‡m© wRGgwc, gvb-wbwðZKiY, Jla
welqK AvBb, RvZxq JlabxwZ, Jl‡ai †hŠw³K I wbivc` eënvi,
AZ¨vek¨Kxq Jl‡ai aviYv I ZvwjKv, eë¯’vcÎwenxb Jl‡ai aviYv
I ZvwjKv Ges †KvW Ae dvg©vwmDwUK¨vjm gv‡K©wUs cÖ¨vKwUm welqK
cÖ‡qvRbxq †Kvm© Ges †f‡Uwibvwi WªvMm Gi †ÿ‡Î †f‡Uwibvwi
dvg©v‡KvjwRi †Kvm©- KvwiKzjv‡g welqmg~n AšÍf©y³ Kivi eë¯’v
†bIqv n‡e|
(M) ¯^v¯’¨ I cwievi Kj¨vY gš¿Yvj‡qi gwbUwis Gi AvIZvq Jla
cÖ¯‘ZKvix cÖwZôvbmg~n Zv‡ì Av‡qi GKwU wbw`©ó cwigvY Ask
Jl‡ai Research and Development G RwoZ e¨w³, miKvwi,
†emiKvwi I ¯^vqËkvwmZ cÖwZôvb‡K cÖ`vb Ki‡e|
4.13 dvg©v‡KvwfwR‡jÝ A_ev Jl‡ai weiƒc cÖwZwµqvmg~‡ni (Adverse Drug

Reactions-ADR) Dchy³ cwiexÿY
(K) evsjv‡`‡ki eëüZ mKj Jl‡ai Rb¨ RvZxq ch©v‡q
dvg©v‡KvwfwR‡jÝ Kvh©µg †Rvi`vi Kiv n‡e| Jla cÖkvmb
Awa`ß‡ii (DGDA) Aax‡b we`¨gvb Adverse Drug Reactions
Monitoring (ADRM) Cell-†K AviI kw³kvjx Kiv n‡e| †`‡ki
nvmcvZvj I wK¬wbKmg~n, wPwKrmK I dvg©vwm÷e„›`mn Ab¨vb¨ ¯^v¯’¨
†mev cÖ`vbKvixMY, †ivMx, Jla cÖ¯‘ZKvix, evRviRvZKvix cÖwZôvb I
dv‡g©mxmg~n wbqwgZfv‡e ADRM Cell-†K GZwØlqK Z_¨, DcvË I
wi‡cvU© w`‡q mnvqZv cÖ`vb Ki‡e|
(L) 100 ev Zvi †ewk kh¨vwewkó †`‡ki me miKvwi I †emiKvwi
nvmcvZv‡j Jl‡ai weiƒc cÖwZwµqv gwbUwis Gi Rb¨ Ô†dvKvj c‡q›UÕ
wba©viY Kiv n‡e| GKwU †gwW‡Kj K‡jR‡K G welqK RvZxq †K›`ª
(National Centre) †NvlYv K‡i G Kvh©µg kw³kvjx Kiv n‡e|
cieZ©x‡Z ch©vqµ‡g mKj nvmcvZv‡j G Kvh©µg MÖnY Kiv n‡e|
(M) ch©vqµ‡g †`‡ki cÖwZwU we‡klvwqZ, †gwWK¨vj K‡jR I †Rjv
ch©v‡qi nvmcvZv‡j wPwKrmK I dvg©vwm÷‡ì mgš^‡q Ôdv‡g©wm GÛ
†_ivwcDwUKm KwgwUÕ MVb Kiv n‡e|
(N) Jla Drcv`Kvix I evRviRvZKvix cÖwZôvbmg~n KZ…©K Zv‡ì wbR¯^
dvg©v‡KvwfwR‡jÝ Kvh©µg cwiPvjbv Kivi eë¯’v †bIqv n‡e|
(O) Jla cÖkvmb Awa`ß‡ii ZË¡veav‡b GKwU RvZxq Jla Z_¨ †K›`ª
(National Drug Information Centre) cÖwZôv Kiv n‡e|
4.14| Jla Drcv`bKvix cÖwZôv‡bi `ÿ Rbej

(K) wek¦ ¯^v¯’¨ ms¯’vi GMP MvBW jvBb Abyhvqx A¨v‡jvc¨vw_K Jla
Drcv`bKvix KviLvbvq cÖ‡qvRbxq msL¨K ¯œvZK wWMÖxavix
dvg©wm÷mn `ÿ Rbej wb‡qvM wbwðZ Kiv n‡e|
(L) Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jla

Drcv`bKvix KviLvbvq Avqy‡e©` ¯œvZK (BAMS), Avqy‡e©` wW‡cøvgv
(DAMS), BDbvbx ¯œvZK (BUMS), BDbvbx wW‡cøvgv (DUMS),
†nvwgIc¨vw_ ¯œvZK (BHMS), †nvwgIc¨vw_ wW‡cøvgv (DHMS),
wWMÖxavix, gvB‡µvev‡qvjwR, dv‡g©mx, †evUvbx, †Kwgw÷ª, ev‡qv‡Kwgw÷ª
Ges A¨vcøvBW †Kwgw÷ª wel‡q m¤§vbmn ¯œvZK wWMÖxavix cÖ‡qvRbxq
msL¨K gvb-wbqš¿Y Ges Drcv`b Kg©KZ©v wb‡qvM Ki‡Z n‡e|
4.15| Jla ißvwb

(K) †`‡k Drcvw`Z Jl‡ai ißvwb DrmvwnZ Kiv n‡e Ges ißvwb e„w×‡Z
cÖ‡Yv`bv cÖ`vb Kiv n‡e|
(L) Jl‡ai ißvwb welqK me ïé I Aïé cÖwZeÜKZv `~i Kivi eë¯’v
MÖnY Kiv n‡e|
(M) Jla ißvwbi †ÿ‡Î Avg`vwbKviK †`‡ki Pvwn`vi cwi‡cÖwÿ‡Z BwáZ
Jl‡ai †iwR‡÷ªkb cÖ`vb Kiv hv‡e| Z‡e wek¦ ¯^v¯’¨ ms¯’vmn
AvšÍR©vwZKfv‡e ¯^xK…Z †Kvb cÖwZôvb KZ©„K †NvwlZ gvbe ev Ab¨
†Kvb cÖvYx‡`‡n A_ev cwi‡e‡ki Rb¨ ÿwZKi †Kvb Jl‡ai
†iwR‡÷ªkb cÖ`vb ev ißvwbi Aby‡gv`b †Ìqv n‡e bv|
(N) Avg`vwbKviK †`‡k evsjv‡`‡ki Jla Drcv`bKvix cÖwZôv‡bi wecYb
Kvh©µg cwiPvjbvi Rb¨ ê‡`wkK gy`ªvi wjwgU e„w× I Jl‡ai wecYb
Dbœq‡b (Marketing Promotion) ch©vß bgybv †cÖi‡Yi AbygwZ cÖ`vb
Kiv n‡e|
(O) GKBfv‡e Avqy‡e©w`K, BDbvbx, nve©vj I †nvwgIc¨vw_K Jla Ges
Jl‡ai KuvPvgvj ißvwbi my‡hvM †Ìqv n‡e|
4.16| RvZxq Jla wbqš¿Y cixÿvMvi (National Control Laboratory-NCL)
(K) National Control Laboratory-NCLJl‡ai cixÿv I we‡køl‡Yi
Rb¨ †K›`ªxq cixÿvMv‡ii f~wgKv cvjb Ki‡e| AvaywbK my‡hvM-myweav,
Dchy³ hš¿cvwZ I `ÿ Rbej mgš^‡q MwVZ NCL †K WHO Gi
Accreditation AR©‡bi D‡`¨vM †bqv n‡e|
(L) ch©vqµ‡g †`‡ki mKj wefv‡M NCL Gi kvLv ¯’vcb Kiv n‡e|
(M) †K›`ªxqfv‡e GKwU ¯^vqËkvwmZ RvZxq †idv‡iÝ cixÿvMvi cÖwZôv
Kiv n‡e|
(N) BDbvbx, Avqy‡e©w`K, nve©vj I †nvwgIc¨vw_K-ev‡qv‡KwgK Jlamg~‡ni
Rb¨ we‡klvwqZ AvaywbK cixÿvMvi ¯’vcb Kiv n‡e|
(O) WªvM †Uw÷s j¨ve‡iUwi‡Z Avqy‡e©w`q, BDbvbx, nvievj, †nvwgIc¨vw_K
I ev‡qv‡KwgK Jla cixÿvi Rb¨ c„_K †mj m„wó Kiv n‡e|
(P) †idv‡iÝ ÷¨vÛvW©/IqvwK©s ÷¨vÛvW© mnRcÖvc¨ Ges g~j¨ mvkÖ‡qi j‡ÿ¨
RvZxq Jla wbqš¿Y cixÿvMvi (National Control Laboratory)
†K †idv‡iÝ ÷¨vÛvW© Avg`vwb K‡i IqvwK©s ÷¨vÛvW© ˆZwii `vwqZ¡
†Ìqv hv‡e| Gme ÷¨vÛvW© Zviv Jla †Kv¤úvwbi Kv‡Q cÖ‡qvRb
Abyhvqx wewµ Ki‡Z cvi‡e| cvkvcvwk Jla Drcv`bKvix cÖwZôvb‡K
†idv‡iÝ ÷¨vÛvW©/IqvwK©s ÷¨vÛvW© Avg`vwbi AbygwZ cÖ`v‡bi eZ©gvb
cÖwµqvI Ae¨vnZ _vK‡e|
(Q) miKvwi, †emiKvwi I ¯^vqËkvwmZ ch©v‡qi mÿg M‡elYv cÖwZôvb‡K
AvaywbK I Uª¨vwWkbvj Jl‡ai cixÿv I we‡køl‡Yi Rb¨ NCL Gi
†idv‡iÝ cixÿvMvi wn‡m‡e m¤ú„³ Kiv n‡e|
(R) mÿg M‡elYv ms¯’v wn‡m‡e AvaywbK I Uª¨vwWkbvj Jl‡ai cixÿv,

we‡kølY I †idv‡iÝ cixÿvMv‡ii Kv‡Ri mv‡_© wewmGmAvBAvi
(Bangladesh Council of Scientific and Industrial Research-
BCSIR)-†K m¤ú„³ Kiv n‡e|
4.17| A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx I †nvwgIc¨vw_K Jl‡ai Rb¨ Avjv`v

Avjv`v AZ¨vek¨Kxq Jl‡ai ZvwjKv cÖYqb
†`‡ki Rb¯^v¯’¨ Kvh©Kifv‡e iÿvi ¯^v‡_©, we‡kl K‡i msL¨vMwiô gvby‡li
Riæwi cÖ‡qvRb, mnRjf¨Zv I µqÿgZv we‡ePbv K‡i †`‡k cÖPwjZ me
wPwKrmv c×wZi (A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx I †nvwgIc¨vw_K)
Jl‡ai gvS †_‡K evQvB K‡i wKQz msL¨K Jla‡K ÔAZ¨vek¨Kxq Jl‡ai
ZvwjKvÕ wn‡m‡e cÖKvk Kiv nj (cwiwkó 1, 2, 3, 4)| wek¦ ¯^v¯’¨ ms¯’vi
mycvwikgvjv I ¯^ ¯^ c×wZi mswkøó we‡klÁ‡ì gZvgZ Abyhvqx cÖwZ
`yÕeQi cici GB ZvwjKv nvjbvMv` Kiv n‡e| †f‡Uwibvwi WªvMm Gi †ÿ‡Î
†f‡Uwibvwi wPwKrmv we‡klÁ‡ì gZvgZ MÖnYc~e©K AZ¨vek¨Kxq †f‡Uwibvwi
Jl‡ai ZvwjKv cÖYqbc~e©K cÖKvk Kiv n‡e Ges h_v wbq‡g nvjbvMv` Kiv n‡e|
cÖ‡qvRb Abyhvqx AZ¨vek¨Kxq Jl‡ai Drcv`b I mieivn wbwðZ Kiv n‡e|
RvZxqfv‡e AZ¨vek¨Kxq Jl‡ai ZvwjKv cÖYq‡bi †gŠjbxwZ MÖn‡Yi j‡ÿ¨
¯^v¯’¨ I cwievi Kj¨vY gš¿Yvj‡qi mwPe Gi mfvcwZ‡Z¡ wewfbœ †gwW‡Kj
K‡j‡Ri Aa¨ÿ, wewfbœ wel‡q we‡klÁ, wek¦we`¨vj‡qi Aa¨vcK, mswkøó
†ckvRxwe msMV‡bi cÖwZwbwa, BDbvbx-Avqy‡e©w`K I †nvwgIc¨vw_K †ev‡W©i
cÖwZwbwa, gnvcwiPvjK-¯^v¯’¨ Awa`ßi, gnvcwiPvjK-cÖvwY m¤ú` Awa`ßi Ges
gnvcwiPvjK-Jla cÖkvmb Awa`ßi mgš^‡q GKwU KwgwU MVb Kiv n‡e|
4.18| Over-the-counter (OTC) Jla
(K) mvaviYfv‡e eëüZ Ges Kg cvk¦©-cÖwZwµqvwewkó Jla †cÖmwµckb
e¨wZ‡i‡K weµ‡qi Rb¨ †`‡k wbewÜZ A¨v‡jvc¨vw_K, Avqy‡e©w`K I
BDbvbx wPwKrmv c×wZi Jl‡ai gvS †_‡K evQvB K‡i wKQz msL¨K
Jla‡K Over the counter (OTC) Jla wn‡m‡e †kÖwYfz³ K‡i
cÖKvk Kiv nj (cwiwkó 5, 6, 7)| wek¦ ¯^v¯’¨ ms¯’vi mycvwik I
mswkøó we‡klÁ‡ì gZvgZ Abyhvqx Jla cÖkvmb Awa`ßi KZ©„K
mgq mgq G ZvwjKv nvjbvMv` Kiv n‡e| †f‡Uwibvwi WªvMm Gi
†ÿ‡Î †f‡Uwibvwi wPwKrmvq we‡klÁ‡ì gZvg‡Zi wfwË‡Z Over the
counter (OTC) Jl‡ai ZvwjKv cÖYqbc~e©K cÖKvk Kiv n‡e Ges
h_v wbq‡g nvjbvMv` Kiv n‡e|
(L) †nvwgIc¨vw_K Jla jÿY-wbf©i nIqvq Ges wPwKrm‡Ki civgk© Qvov
eënv‡ii †ÿ‡Î †ivMxi ÿwZi m¤¢vebv _vKvq eë¯’vcÎwenxb
†nvwgIc¨vw_K Jl‡ai ZvwjKv cÖYq‡bi cÖ‡qvRb bvB|
4.19| Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jl‡ai gvb

Dbœq‡b wRGgwc bxwZgvjv Ges êÁvwbK cÖhyw³-wbf©i gvb-wbqš¿Y eë¯’v
(K) Avqy‡e©w`K, BDbvbx, †nvwgIc¨vw_K I nve©vj Jl‡ai Drcv`‡bi †ÿ‡Î
wek¦ ¯^v¯’¨ ms¯’vi GMP Guideline for Herbal Medicinal
Products AbymiY Kiv n‡e| mvwe©K Ae¯’v we‡ePbvq AvMvgx 5 (cuvP)
erm‡ii Rb¨ GKwU AšÍe©Zx©Kvjxb wRGgwc bxwZgvjv ˆZwi Kiv n‡e|
G wel‡q Jla cÖkvmb Awa`ßi mswkøó we‡klÁ‡ì mgš^‡q GKwU
KwgwU MVb Ki‡e|
(L) Avqy‡e©w`K, BDbvbx, †nvwgIc¨vw_K I nve©vj Jl‡ai †ÿ‡Î †R‡bwiK
bv‡gi cvkvcvwk Jl‡ai †j‡ej I KvU©‡b ÔAvqy‡e©w`K JlaÕ ev
ÔBDbvbx JlaÕ ev Ô†nvwgIc¨vw_K-ev‡qv‡KwgK JlaÕ ev Ônve©vj JlaÕ
my¯úófv‡e D‡jøL Kwi‡Z n‡e|
(M) Avqy‡e©w`K, BDbvbx I nve©vj Jl‡ai †ÿ‡Î Avqy‡e©w`K I BDbvbx
dg~©jvwi‡Z DwjøwLZ Dcv`vb Qvov mwµq Dcv`vb (Active Ingredient)
wn‡m‡e Ab¨ †Kv‡bv ivmvqwbK Dcv`vb eënvi Kiv hv‡e bv|
(N) Avqy‡e©w`K, BDbvbx, †nvwgIc¨vw_K-ev‡qv‡KwgK I nve©vj Jl‡ai
gvbwbqš¿‡Yi †ÿ‡Î KuvPvgvj, B›UviwgwW‡qU cÖWv± Ges Drcvw`Z
Jl‡ai †U÷ µvB‡Uwiqv Ges †¯úwmwd‡Kkb we‡klÁ‡ì mnvqZvq
wek¦ ¯^v¯’¨ ms¯’vi cÖ¯Ívebv Ges gvwK©b hy³ivóª, d«vÝ, Rvg©vwb, MYPxb I
fvi‡Z cÖPwjZ c×wZ AbymiY K‡i cÖYqb Kiv n‡e|
(O) wek¦ ¯^v¯’¨ ms¯’vi mswkøó wb‡`©wkZ ÷¨vÛvW© µvB‡Uwiqvi wfwË‡Z;
Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jla
Drcv`bKvix cÖwZôvbmg~‡ni cÖhyw³MZ I AeKvVv‡gvMZ myweavw`
we‡ePbv K‡i mÿgZv Abyhvqx †kÖwYweb¨vm Kiv n‡e|
(P) †`wkq †nvwgIc¨vw_ wk‡íi weKv‡ki Rb¨ †`‡k Drcvw`Z †nvwgI
Jl‡ai gvb DbœZ Kiv n‡e| gvwK©b hy³ivóªmn DbœZ †`kmg~‡ni
†nvwgIc¨vw_K dvg©v‡Kvwcqv Aej¤^‡b we‡klÁ‡ì Øviv Test Criteria
wba©viY Kiv n‡e Ges GB Test Criteria Abyhvqx Jla cixÿ‡Y
Drcv`K‡ì wb‡`©k †Ìqv n‡e|
(Q) Avqy‡e©w`K, BDbvbx, nve©vj I †nvwgIc¨vw_K Jla Drcv`‡b †Kv‡bv
Aby‡gvw`Z ivmvqwbK Dcv`vb (†÷i‡qW, ni‡gvb, †hŠb D‡ËRK A_ev
Ab¨ †Kvb ivmvqwbK Dcv`vb) eënvi Kiv hv‡e bv| GQvov Gme
Jly‡a GdwWwm Kvjvi ev mvwU©dvBW dzW/dvg©v †MÖ‡Wi Kvjvi e¨ZxZ
Ab¨ †Kv‡bv Kvjvi ev †d¬fvi eënvi Kiv hv‡e bv|
(R) A¨vj‡Kvn‡ji Aceënvi †iv‡a †nvwgIc¨vw_K gv`vi wUsPvi Ges Jla
kw³Ki‡Yi †ÿ‡Î †KejgvÎ †nvwgIc¨vw_K †idv‡iÝ eBmg~‡ni
wb‡`©kbv Abymv‡i cÖ‡qvRbxq B_vBj A¨vj‡Kvnj (†iKwUfv‡qW w¯úwiU)
eënv‡ii Aby‡gv`b †Ìqv n‡e| A¨vn‡Kvnjhy³ †nvwgIc¨vw_K
kw³K…Z (c‡UwÝ/WvBjykb) Jl‡ai c¨vK mvBR 30 wg:wj: Gi †ekx
Aby‡gv`b †Ìqv n‡e bv|
4.20| Jlwa¸Y m¤úbœ Dcv`vbhy³ I †ivM wb‡`©kK…Z cY¨‡K Jla wnmv‡e MY¨ Kiv
(K) Jlwa¸Y m¤úbœ Dcv`vbhy³ I †ivM wb‡`©kK…Z Ges dvg©vwmDwUK¨vj

†Wv‡Rm d‡g© Drcvw`Z cY¨ Food or Nutritional or Herbal or
Natural mvwcø‡g›Umg~n‡K Jla cÖkvmb Awa`ß‡ii wbqš¿‡Y Avbv n‡e|
(L) DwjøwLZ Food or Nutritional or Herbal or Natural

mvwcø‡g›Umg~n Drcv`b I Avg`vwbi †ÿ‡Î Jla cÖkvmb Awa`ß‡ii
wb‡`©kvejx AbymiY Ki‡Z n‡e| Drcv`‡bi †ÿ‡Î RvZxq Jla
wbqš¿YKvix KZ©„c‡ÿi cÖYxZ wRGgwc bxwZgvjv I gvb-wbqš¿Y kZ©vejx
cÖ‡hvR¨ n‡e| DwjøwLZ KZ©„c‡ÿi Aby‡gv`bnxb c‡Yï Drcv`b, Avg`vwb,
weZiY, gRy` I wewµ wbwl× I kvw¯Í‡hvM¨ Kiv n‡e|
4.21| †gwW‡Kj wWfvBm I mvwR©K¨vj BKzBc‡g›U Avg`vwb
(K) kix‡ii Af¨šÍ‡i Ges evB‡i †hme †gwWK¨vj wWfvBm I mvwR©K¨vj

BKzBc‡g›U †ivM wbY©q, wbivgq I cÖwZ‡iv‡ai Rb¨ ¯’vcb/ms‡hvRb I
eënvi Kiv nq †mme wWfvBm I BKzBc‡g›U Jla cÖkvmb Awa`ß‡ii
wbqš¿Yfz³ _vK‡e|
(L) †gwWK¨vj wWfvBm I mvwR©K¨vj BKzBc‡g›U Avg`vwbi Rb¨

Drcv`bKvix cÖwZôv‡bi Bmy¨K…Z wRGgwc mvwU©wd‡KU (†Kv‡bv †`‡k
wRGgwc mvwU©wd‡KU cÖ`v‡bi cÖ_v bv _vK‡j †m †ÿ‡Î Dchy³
KZ©„c‡ÿi mb`/†iwR‡÷ªkb mb`) `vwLj Ki‡Z n‡e|
(M) †gwWK¨vj wWfvBm I mvwR©K¨vj BKzBc‡g›U Avg`vwb †iwR‡÷ªk‡bi
†ÿ‡Î Jla cÖkvmb Awa`ßi KZ©„K cÖYxZ ‘Registration Guideline
for Medical Devices, Bangladesh-2015’ AbymiY Ki‡Z n‡e|
4.22| Jl‡ai wK¬wbK¨vj Uªvqvj (Clinical Trial) I ev‡qvBKzf¨v‡jÝ cixÿY

(Bio-equivalence Study)
Jl‡ai ¸YMZ gvb I Kvh©KvwiZv m¤ú‡K© wbwðZ nIqvi j‡ÿ¨ Jl‡ai

ev‡qvBKzf¨v‡jÝ cixÿv Avek¨K nIqvq G j‡ÿ¨ AwZ`ªæZ Globally
Accredited ev‡qvBKzf¨v‡jÝ I wK¬wbK¨vj cixÿv †K›`ª (Bioequivalence
Study Centre and Clinical Trial Centre) ¯’vcb Kivi D‡`¨vM †bIqv
n‡e| G †ÿ‡Î miKvwi I †emiKvwi D‡`¨vM‡K DrmvwnZ Kiv n‡e| Jl‡ai
Bioequivalence Study and Clinical Trial cwiPvjbvi j‡ÿ¨ Jla
cÖkvmb Awa`ßi KZ©„K cÖYxZ MvBWjvBb AbymiY Ki‡Z n‡e| D³
MvBWjvBb mgq mg‡q nvjbvMv` Kiv n‡e|
4.23| WTO/TRIPS Pzw³i Av‡jv‡K evsjv‡`‡ki Jla wkíweKv‡k mnvqZv Kiv

(K) Jl‡ai cyi‡bv †c‡U›U AvBb‡K Rb¯^v‡_© hy‡MvchyMx Kiv n‡e| wek¦
evwYR¨ ms¯’vi †gav¯^Z¡ I evwYR¨ AvBb ev wUªcm Pzw³i Av‡jv‡K
evsjv‡`‡ki Jla †m±i‡K cÖ¯‘Z Kiv n‡e|
(L) Uª¨vwWkbvj †gwWwmb wn‡m‡e eëüZ G‡`‡ki †fŠ‡MvwjK mxgvbvq
Rb¥v‡bv MvQ-MvQov, Jlywa Dcv`vb I G¸‡jvi dg~©jv Avgv‡ì HwZn¨
I ms¯‹…wZi Ask Ges AvBbMZfv‡e Avgv‡ì wbR¯^ †flR m¤ú`|
RvZxq m¤ú` I Rb¯^v¯’¨ iÿvi ¯^v‡_© G¸‡jvi †gav¯^Z¡ AR©‡b
miKvwifv‡e AbwZwej‡¤^ D‡`¨vM MÖnY Kiv n‡e|
4.24| Lv`¨ I Jla cÖkvmb Awa`ß‡i iƒcvšÍi I mvsMVwbK KvVv‡gv cybwe©b¨vm

(K) Rb¯^v¯’¨ iÿvi Rb¨ Jl‡ai cvkvcvwk wewfbœ K¨vUvMwii cÖwµqvRvZ
Jla mswkøó Lv‡`ï Drcv`b, Avg`vwb, gvb-wbqš¿Y, gRy`, weµq I
weZiY wbqš¿Y AZ¨šÍ ¸iæZ¡c~Y© weavq we`¨gvb AvB‡bi cÖ‡qvRbxq
ms‡kva‡bi gva¨‡g Jla cÖkvmb Awa`ßi‡K ÔLv`¨ I Jla cÖkvmbÕ
(Food & Drug Administration) Awa`ß‡i iƒcvšÍi Kiv n‡e|
(L) cÖwµqvRvZ Jla mswkøó Lv`¨, dzW mvwcø‡g›U, wbDUªvwmDwUK¨vjm, wcÖ-
ev‡qvwUK I †cÖvev‡qvwUK, †gwW‡Kj wWfvB‡mm, mvwR©K¨vj BKzBc‡g›Um,
wfUvwgb wcÖ-wg· BZ¨vw` cÖ¯ÍvweZ G Awa`ß‡ii wbqš¿Yfz³ n‡e|
(M) gvbe‡`‡ni Physiological cwieZ©b mvab K‡i e‡j `vexK…Z Jla
mswkøó cÖmvab mvgMÖx Jla cÖkvmb Awa`ß‡ii wbqš¿Yfz³ Kiv n‡e|
4.25| Jla Drcv`K KZ…©K cwi‡ek `~lY‡iv‡a eR©¨ cwi‡kvab eë¯’v wbwðZ Kiv
(K) Jla Drcv`K‡ì KZ…©K cwi‡ek `~lY cÖwZ‡iv‡a, Rb¯^v‡¯’ï
ÿwZ‡iva Ki‡Z me ¯^xK…Z c×wZi Jla KviLvbvi eR©¨ cwi‡kvab
eë¯’v _vK‡Z n‡e|
(L) cwi‡ek `~lY Kgv‡Z Jla †Kv¤úvbx hv‡ì KviLvbv eZ©gv‡b AvevwmK
GjvKvq i‡q‡Q Zv‡ì‡K AvMvgx 5 (cuvP) erm‡ii g‡a¨ †mme
KviLvbv wkí ev AbvevwmK GjvKvq mwi‡q wb‡Z n‡e|
(M) mKj Jla cÖ¯‘ZKvix cÖwZôv‡b Aek¨B B.wU.wc. (Effluent
Treatment Plant-ETP) _vK‡Z n‡e| mwjW I‡q÷ wWm‡cvRv‡ji
†ÿ‡Î Bbwmbv‡iUi ¯’vcb DrmvwnZ Kiv n‡e, Z‡e G j‡ÿ¨ Ab¨ †Kvb
cÖwZôv‡bi Bbwmbv‡iU‡i Pzw³wfwËK wWm‡cvRv‡jiI Aby‡gv`b †Ìqv
hv‡e|
4.26| cÖvwYm¤ú` I grm¨ wPwKrmvq eëüZ Jla

(K) cÖvwYm¤ú` wPwKrmvq Jla Drcv`‡b wRGgwc †gvZv‡eK gvb-wbqš¿‡Yi
cÖ‡qvRbxq eë¯’v MÖnb Kiv n‡e|
(L) cÖvwY‡`‡n I grm¨ wPwKrmvq eëüZ Jl‡ai †j‡ej, wjUv‡iPvi I
†gvoK mvgMÖx‡Z eënviwewa mywbw`©ó Ki‡Z n‡e Ges cÖvwYm¤ú‡`
eëüZ Jla gr‡m¨ eënvi wbiyrmvwnZ Kiv n‡e|
(M) Veterinary Medicinal Product (VMP) Gi gr‡m¨ eënvi
wbiyrmvwnZ Kivi mv‡_ mv‡_ wPwKrmvi Rb¨ Aquaculture Medicinal
Product (AMP) Gi Drcv`b e„w×i Rb¨ Jla Drcv`bKvix
cÖwZôvb¸‡jv‡K wb‡`©kbv cÖ`vb Kiv n‡e|
4.27| Rb¯^v‡¯’ï Rb¨ ÿwZKi Jla evwZj Kiv
(K) mKj c×wZi Jl‡ai †ÿ‡Î mg‡q mg‡q wba©vwiZ wbq‡g Jl‡ai
wbivcËv (Safety) g~j¨vqb K‡i eënvi wb‡`©kbv (Indications), gvÎv
(Dose), kw³ (Strength/Potency), Dc¯’vcb (Dosage Form)
ms‡kvab Kiv n‡e|
(L) wewfbœ AvšÍR©vwZK cÖwZôvb †hgb wek¦ ¯^v¯’¨ ms¯’v (WHO), USFDA,
UKMHRA, TGA, Australia, Health Canada, EMEA Ges
Abyiƒc AvšÍR©vwZK gv‡bi Jla wbqš¿Y KZ…©cÿ KZ…©K †NvwlZ ÿwZKi
Jla¸‡jv Jla wbqš¿Y KwgwUi (DCC) gva¨‡g g~j¨vqbc~e©K G¸‡jvi
†iwR‡÷ªkb evwZj Kiv n‡e|
(M) Rb¯^v‡¯’ï Rb¨ ÿwZKi A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx, nve©vj,

†nvwgIc¨vw_K I ev‡qv‡KwgK Jla, Jla wbqš¿Y KwgwUi (DCC)
gva¨‡g cybg~©j¨vqbc~e©K evwZj Kiv n‡e|
5| Dcmsnvi
RvZxq JlabxwZ-2005 ch©v‡jvPbv K‡i JlabxwZ-2016 cÖYqb Kiv n‡q‡Q| G

JlabxwZ‡Z Jl‡ai wbivcËv (Safety), Kvh©KvwiZv (Efficacy), †hŠw³K eënvi,
Kvh©Ki Jla wbqš¿Y eë¯’v, Jla Drcv`b, wecYb, weZiY, msiÿY Ges Jla Avg`vwb-
ißvwbi †ÿ‡Î my¯úó w`Kwb‡`©kbv i‡q‡Q| G JlabxwZi d‡j Jla wk‡íi AviI weKvk
NU‡e, †`k AwaKZi gvb-m¤úbœ Jla Drcv`‡b mg_© n‡e Ges Jla ißvwbi m¤¢vebv
A‡bK¸Y e„w× cv‡e|
cwiwkó-1
AZ¨vek¨Kxq Jl‡ai ZvwjKv (A¨v‡jvc¨vw_K)
List of Essential Drugs (Allopathic)
Sl. 1. ANAESTHETICS
No.
1.1 General anaesthetics and oxygen
1.1.1 Inhalational medicines
1 Halothane
2 Nitrous Oxide-Oxygen for Anaesthesia
3 Oxygen Inhalation
1.1.2 Injectable medicines
4 Thiopental Sodium Injection
5 Ketamine Injection
1.2 Local anaesthetics
6 Lignocaine with or without Adrenaline Injection 1% and 2%
7 Procaine Hydrochloride Injection (Various Strengths)
8 Bupivacaine Hydrochloride Injection
1.3 preoperative madication and sedation for short-term procedures
9 Atropine Sulphate Injection
10 Morphine Sulphate Injection
2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-
INFLAMMATORY MEDICINES (NSAIMs), MEDICINES USED
TO TREAT GOUT AND DISEASE MODIFYING AGENTS IN
RHEUMATOID DISORDERS (DMARDs)
2.1 Non-opioids and non-steroidal anti inflammatory medicines
(NSAIMs)
11 Aspirin Tablet 75-100 mg
12 Paracetamol Tablet/Syrup/Suspension/
Suppository
13 Pethidine Hydrochloride Injection
14 Indomethacin Capsule/Suppository/Sustained
Release Tablet
15 Ibuprofen Tablet
16 Naproxen Tablet
2.2 Opioid analgesics
SL No-10
2.3 Medicines used to treat gout
17 Allopurinol Tablet
18 Colchicine Tablet
2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)
19 Penicillamine Tablet
20 Sulphasalazine Tablet
21 Sodium Aurothiomalate Injection
22 Methotrexate Tablet/Injection
23 Chloroquine Oral liquid/Tablet
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
24 Chlorpheniramine Maleate Tablet/Syrup/Injection
25 Prednisolone Tablet
26 Dexamethasone Tablet/Cream/Injection
27 Hydrocortisone Injection/Cream/Ointment
28 Promethazine Hydrochloride Tablet/Injection
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
4.1 Non-specific
29 Activated Charcoal Tablet
4.2 Specific
30 Naloxone Hydrochloride Injection
31 Pralidoxime Mesylate Injection
SL No-09 Injection/Eye drop/ointment
5. ANTICONVULSANTS/ANTIEPILEPTICS
32 Phenobarbitone Tablet/Injection
33 Phenytoin Tablet/Capsule/Elixir
34 Ethosuximide Capsule
35 Magnesium Sulphate 50% Injection
6. ANTI-INFECTIVE MEDICINES
6.1 Anthelminthics
6.1.1 lntestinal anthelminthics
36 Mebendazole Tablet
37 Albendazole Chewable Tablet
38 Levamisole Tablet/Syrup
39 Niclosamide Tablet
6.1.2 Antifilarials
40 Diethylcarbamazine Tablet/Suspension
SL No-37
6.2 Antibacterials
6.2.1 Beta Lactam medicines
41 Amoxycillin Capsule/dry Syrup/Injection
42 Ampicillin Capsule/dry Syrup/Injection
43 Phenoxymethyl Penicilln Tablet/Syrup
44 Benzathine Penicillin Injection
45 Flucloxacillin Capsule/Syrup/Injection
46 Procaine Penicillin Injection
47 Cephradine Capsule/Syrup/Injection
48 Cephalexin Capsule/Tablet/Syrup
49 Benzyl Penicillin Injection
50 Cloxacillin Capsule/Syrup/Injection
51 Amoxiclav Tablet/Capsules/Dry Syrup/
Injection
6.2.2 Other antibactarials
52 Erythromycin Tablet/Oral Suspension/
Injection
53 Chloramphenicol Eye/Ear Drops/Ointment
54 Doxycycline Capsule
55 Co-Trimoxazole Tablet/Suspension
56 Metronidazole Tablet/Oral Liquid/Injection
57 Tetracycline/Oxytetracycline Capsule/Injection
Hydrochloride
58 Nalidixic Acid Tablet/Syrup
59 Trimethoprim Tablet/Suspension/Injection
6.2.3 Antileprosy medicines
60 Clofazimine Capsule
61 Dapsone Tablet
6.2.4 Antituberculosis medicines
62 Ethambutol Tablet
63 lsoniazid with or without Ethambutul Tablet
64 Pyrazinamide Tablet
65 Rifampicin With or without Isoniazid Tablet
66 Streptomycin Sulphate Injection
67 Rifampicin+lsoniazid+Pyrazinamide combination Tablet
with or without Ethambutol
68 Rifampicin+Isoniazid+Ethambutol Tablet
6.3 Antifungal medicines
69 Griseofulvin Tablet
70 Clotrimazole Cream/Pessaries/Solution/
Dusting Powder
71 Nystatin Tablet/Suspension/Cream/Gel
72 Preparations of Imidazole or Nystatin for Vaginal and Vulval Candidiasis
6.4 Antiviral medicines
73 Acyclovir Tablet/Cream/Eye ointment
Intravenous Infusion
74 Nelfinavir (NVP) Oral powder/tablet
6.4.1 Antiherpes medicines
75 Idoxruridine Eye Drops
6.4.2 Antiretrovirals
6.4.2.1 Nucleoside/Nucleotide reverse transscriptase inhibitors
76 Abacavir (ABC) Oral liquid/Tablet
77 Lamivudine(3TC) Oral liquid/Tablet
78 Tenofovir disoproxil fumarate (TDF) Tablet
79 Zidovudine (ZDV or AZT) Capsul/Oral liquid/IV
infusion/injection/Tablet
6.4.2.2 Non-nucleoside reverse teanscriptase inhibitors
80 Efavirenz Capsul/Oral liquid/Tablet
81 Nevirapine(NVP) Oral liquid/Tablet
6.4.3 Other antivirals
82 Oseltamivir Tablet
6.5 Antiprotozoal medicines
6.5.1 Antiamoebic and antigiardiasis medicines
83 Diloxanide Tablet
6.5.2 Antileishmaniasis medicines
84 Sodium Stibogluconate Injection
6.5.3 Antimalarial medicines
6.5.3.1 For curative treatment
85 Artemether with Lumefantrine Tablet
86 Primaquine Tablet
87 Sulfadoxin with Pyrimethamine Tablet
88 Artesunate Injection/Tablet
89 Mefioquine Tablet
90 Quninie Injection/Tablet
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines
91 Pyrimethamine Tablet
7. ANTIMIGRAINE MEDICINES
7. 1 For treatment of acute attack
92 Sumatriptan Succinate Tablet/Injection/Nasal Spray
93 Acetylsalicylic acid Suppository/Tablet
SL No-11
SL No-12
7.2 For prophylaxis
94 Propranolol Tablet
8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES
USED IN PALLIATIVE CARE
8. Immunosuppressive medicines
95 Azathioprine Tablet/Injection
96 Cyclosporin Capsule/Oral Solution/
IV Infusion
8.2 Cytotoxic and adjuvant medicines
97 Actinomycin D/Dactinomycin Injection
98 Bleomycin Injection
99 Calcium Folinate/Calcium Leucovorin Tablet/Injection
100 Cyclophosphamide Tablet
101 Busulphan Tablet
102 Cisplatin Injection
103 Chlorambucil Tablet
104 Crisantaspase/L-asparaginase Injection
105 Thioguanine Tablet
106 Vinblastine Sulphate Injection
107 Vincristine Sulphate Injection
108 Doxorubicin Injection
109 Mercaptopurine Tablet
110 Lomustine Capsule
111 Melphalan Tablet/Injection
112 Mitomycin Injection
113 Mustine Hydrochloride Injection
8.3 Hormones and antihormones
114 Tamoxifen Tablet/Capsule
115 Vasopressin Injection
116 Liothyronine Sodium Tablet/Injection
117 Stilboestrol/Diethylstilboestrol Tablet
SL No. 26 Injection
SL No. 27 Injection
8.4 Medicines used in palliative care
118 Hyoscine butylbromide Tablet/Injection
119 Amitryptyline Tablet
120 Propanththeline Bromide Tablet
121 Lactulose Powder/Solution
SL No. 26 Tablet/Injection
9. ANTIPARKINSONISM MEDICINES
122 Levodopa with Carbidopa Tablet
10. MEDICINES AFFECTING THE BLOOD

10.1 Antianaemia medicines
123 Ferrous Sulphate/Fumarate, with or Tablet/Syrup
without Folic Acid
124 Folic Acid Tablet
10.2 Medicines affecting coagulation
125 Heparin Injection
126 Dipyridamole Tablet/Oral Suspension/
Injection
127 Protamine sulfate Injection
11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES
11.1 Plasma substitutes
128 ACD Blood Pack/Double Bag/ Triple Bag
129 Plasma Substitutes/Dextran-40/
Succinylated Gelatin Intravenous
Infusions
130 Dextran 70 Injection
11.2 Plasma fractions for specific use
131 Plasma Fractions/Human Albumin Solution for IV infusion
12. CARDIOVASCULAR MEDICINES

12.1 Antianginal medicines
132 Metoprolol Tartrate Tablet
133 Glyceryl Trinitrate Tablet/Spray
134 Isosorbide dinitrate Tablet/Injection
135 Isosorbide mononitrate Tablet
12.2 Antiarrhythmic medicines

136 Procainamide Injection/Capsule
137 Digoxin Tablet/Injection
138 Disopyramide Tablet/Capsule
12.3 Antihypertensive medicines

139 Atenolo Tablet
SL No. 94 Tablet/Injection
140 Methyldopa
141 Captopril Tablet
142 Diazoxide Injection
143 Sodium Nitroprusside Injection
144 Prazocin Hydrochloride Tablet
145 Enalapril Tablet
146 Spironolactone Tablet
147 Hydrochlorothiazide Tablet
12.4 Medicines used in heart failure
148 Dopamine Injection
SL No. 137
SL No. 144
12.5 Antithrombotic medicines
149 Clopidogrel Tablet
12.6 Lipid-lowering agents
150 Simvastatin Tablet
12.7 Anti-Hypotensive medeicine
151 Metarminol Injection
13. DERMATOLOGICAL MEDICINES (topical)
13.1 Antifungal medicines
152 Miconazole Cream/Dusting Powder/
Spray/Oral Gel
153 Sodium thiosulfate Solution
13.2 Anti-infective medicines
154 Potassium Permanganate Crystal/Solution (0.1%)
Sl No. 57 Ointment
155 Silver sulfadiazine Cream
13.3 Anti-inflammatory and antipruritic medicines

156 Calamine Lotion
157 Betamethasone Ointment, Cream
158 Betamethasone with Neomycin Ointment
159 Noemycin sulfate with Bacitracin Ointment/Powder
SL No. 26 Cream
SL No. 27 Cream/Ointment
13.4 Medicines affecting skin differentiation and proliferation
160 Salicylic Acid+Benzoic Acid Ointment, Cream
161 Fluorouracil Capsul/Injection/Cream
162 Salicylic acid Solution
13.5 Scabicides and pediculicides
163 Benzyl Benzoate Lotion
164 Permethrin Cream/Lotion
14. DIAGNOSTIC AGENTS
14.1 Ophthalmic medicines
165 Flurescein Eye drops
166 Tropicamide Eye drops
14.2 Radiocontrast media
167 Barium Sulphate (X-Ray Grade)
168 Lodipamide Injection
169 Lothalmic Acid with Meglumine Oral Solution
15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
170 Chlorhexidine with or without Cetrimide Solution/Cream
171 Povidone-lodine 10% Alcoholic Solution
172 Bismuth, lodoform and Paraffin Paste For Nasal Pack
(BIPP)
15.2 Disnfectants
173 Chloroxylenol Sulution/Cream
16. DIURETICS
174 Frusemide Tablet/Injection
175 Bendrofluazide Tablet
SL No. 146 Tablet/Capsule
176 Mannitol Infusion Solution 10% and 20%
SL No. 147
17. GASTROINTESTINAL MEDICINES
17.1 Antiulcer medicines
177 Aluminium Hydroxide Gel with or Tablet/Suspension
without Magnesium Trisilicate
178 Ranitidine Tablet/Injection
179 Omeprazole Capsul/Tablet/Injection
17.2 Antiemetic medicines
180 Cinnarizine Tablet
181 Metoclopramide Hydrochloride Tablet/Oral
Solution/Injection
182 Prochlorperazine Tablet/Injection
SL No. 28
17.3 Anti-inflammatory medicines
SL No. 20 Suppository
17.4 Laxatives
183 Glycerin/Glycerol Suppository for adult/child/
infant
184 Senna/Sannosides Tablet
17.5 Medicines used in diarrhoea
17.5.1 Oral rehydration
185 Potassium Chloride Tablet/Syrup
186 Sodium Chloride 0.9%, without or with Intravenous infusion
Dextrose
187 Sodium Bicarbonate Infusion (Various Strengths)
17.5.2 Medicines for diarrhoea in children
188 Zinc sulfate Oral liquid/Tablet
18. HORMONES, OTHER ENDOCRINE MEDICINES AND

CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
189 ACTH Injection
SL No. 26 Injection
18.2 Androgens
190 Danazol Capsule
18.3 Contraceptives
18.3.1 Oral hormonal contraceptives
191 Ethinylestradiol + levonorgestrel Tablet: 30 micrograms + 150
micrograms
192 Ethinylestradol + Lynestrenol Tablet 0.0375mg+0.75mg
193 Desogesterol + Ethinylestradiol Tablet : 0.15mg+0.03mg
194 Levonorgestrel Tablet 750microgram
18.3.2 Injectable hormonal contraceptives
195 Depot Medroxyprogesterone Injection
18.3.3 Intrauterine devices
196 Copper-T containing device
18.3.4 Barrier methods
197 Condoms
18.3.5 Implantable contraceptives
198 Levonorgestrel-releasing implant
18.4 Estrogens
199 Oestrogens with or without Progestogens
for HRT
18.5 Insulins and other medicines used for diabetes
200 Glibenclamide Tablet
201 Insulin Various preparations
202 Chlorpropamide Tablet
203 Metformin Hydrochloride Tablet
18.6 Ovulation inducers

204 Clomiphene Citrate Tablet
18.7 Progestogens
205 Medroxyprogesterone acetate Tablet 5mg
18.8 Thyroid hormones and antithyroid medicines
206 Carbimazole Tablet
207 Aqueous lodine Oral Solution (Lugol’s
Solution)
208 Thyroxine sodium Tablet
209 Levothyroxine Tablet
19. IMMUNOLOGICALS
19.1 Diagnostic agents
210 Sodium Diatrozoate with Meglumine Sodium Injection
211 Tuberculin, purified protein derivative Injection
19.2 Sera and immunoglobulins
212 Diphtheria Antitoxin
213 Polyvalent Antivenoms
214 Tetanus Antitoxin Injection (Minimum 10.000
IU Dose)
215 Human Normal Immunoglobulin Injection
19.3 Vaccines
216 BCG Vaccine
217 DPT Vaccine
218 Pentavalent vaccine (DPT, HepatitiesB, Hib)
219 Pneumococcal Vaccine (PCV)
220 Poliomyelitis Vaccine(OPV & IPV)

221 MR Vaccine (Mesales & Rubella)
222 Measles vaccine Injection
223 Hepatitis-B Vaccine Injection
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND

CHOLINESTERASE INHIBITORS
224 Neostigmine Tablet/Injection
225 Suxamethonium Chloride Injection
226 Pancurium Bromide Injection
227 Gallamine Trithiodide Injection
21. OPHTHALMOLOGICAL PREPARATIONS
21.1 Anti-infective agents
228 Framycetin Sulphate Eye Drops/Ointment
229 Gentamycin Injection/Eye Drops/Ointment
230 Tetracaine/Amethocaine Eye Drops
SL No. 53 Eye Drops/Ointment
21.2 Anti-inflammatory agents
231 Corticosteroid Eye Drops/Ointment
SL No. 158 Eye Drops
21.3 Local anaesthetics
SL No. 230
21.4 Miotics and antiglaucoma medicines
232 Pilocarpine Eye Drops (Various Stregths)
233 Acetazolamide Tablet
234 Carbachol Tablet/Eye Drops
SL No. 151
21.5 Mydriatics
235 Phenylephrine Hydrochloride Eye Drops

236 Homatropine Eye Drops
SL No. 09 Injection/eye drop/ointment
22. OXYTOCICS AND ANTIOXYTOCICS
22.1 Oxytocics
237 Trifluperazine Tablet/Oral solution
238 Oxytocin Injection
239 Ergometrine Injection
22.2 Antioxytocics (tocolytics)
240 Nifedipine Capsule
23. PERITONEAL DIALYSIS SOLUTION
241 Intraperitoneal dialysis solution (of Parenteral solution
appropriate composition)
24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychotic disorders

242 Chlorpromazine Hydrochloride Tablet/Syrup/Injection
243 Haloperidol Tablet/Capsule/Oral Liquid
24.2 Medicines used in mood disorders
24.2.1 Medicines used depressive disorders
244 Imipramine Hydrochloride Tablet/Syrup
245 Nortriptyline Tablet
246 Flupenthixol Tablet/Injection
Dihydrochloride/Decanoate
SL No. 119
24.2.2 Medicines used in bipolar disorders
247 Carbamazepine Tablet/Oral Liquid/Suppository
248 Lithium Carbonate/Citrate Tablet/Oral liquid
24.3 Medicines for anxiety disorders

249 Diazepam Tablet/Injection
250 Clobazam Tablet
24.4 Medicines used for obsessive compulsive disorders
251 Clomipramine Hydrochloride Tablet/Syrup/Capsule/Injection
24.5 Medicines for disorders due to psychoactive substance use
252 Methadone Hydrochloride Tablet/Injection
25. MEDICINES ACTING ON THE RESPIRATORY TRACT
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary
disease
253 Salbutamol Tablet/Elixir
254 Adrenaline/Epinephrine Injection
255 Aminophylline Tablet/Injection
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE &
ACID-BASE DISTURBANCES
26.1 Oral
256 Oral Rehydration Salts (ORS) Sachet for 500 ml
257 Cholera Fluid Intravenous Infusion
258 Sodium hydrogen carbonate Injection
26.2 Parenteral
259 Dextrose in Water Intravenous Infusion, 5%, 25%
and 50%
260 Supplemental Parenteral Nutrients For adding to Infusion
261 Glucose Injectable solution
262 Glucose with sodium chloride Injectable soluton
263 Sodium chloride Injectable solution
264 Sodium chloride 3% I/V fluid
265 Sodium chloride quartat strength I/V fluid
(0.225%)+Dextrose 5%
SL No 259 Injectable solution
26.3 Miscellaneous
266 Water for Injection
(sterile/pyrogen free)
267 Dialysis Fluid
27. VITAMINS AND MINERALS
268 Ascorbic Acid/Vitamin C Tablet
269 Vitamin A Capsule 50,000-2,00,000 IU
(Injection 100,000 IU for SL
and above)
270 Vitamin B1 Tablet/Injection
271 Vitamin K Tablet/Injection
272 Vitamin E Tablet
273 Vitamin B-Complex Tablet/Drops
274 Calcium Gluconate Tablet/Injection
275 Lodized Oil Injection
276 Vitamin B12 Injection
277 Nicotinamide Tablet
278 Pyridoxine Tablet
279 Retinol Capsule/Tablet/Oral oily
solution/Water-miscible injection
280 Riboflavin Tablet
281 Thiamine Tablet
SL No- 124
28. EAR, NOSE AND THROAT CONDITIONS IN CHILDREN [C]
282 Ciprofloxacin Eye drops for SL and above
283 Gentamicin + Hydrocortisone Ear Drops
284 Xylometazoline Nasal drops
SL No. 53 Ear Drops/Ointment
29. SPECIFIC MEDICINES FOR NEONATAL CARE [C]
30. MUCOLYTICS, EXPECTORANTS AND COUGH SUPRESSANTS
285 Dextromethorphan Syrup
cwiwkó-2
AZ¨vek¨Kxq Avqy‡e©w`K Jl‡ai ZvwjKv
(List of Essential Ayurvedic Drugs)
1. wÎdjv P‚b© 26. k¦vmKzVvi im
2. Zvwjkvw` P‚b© 27. Kd‡KZz im
3. AwecwËKi P‚b© 28. wchyl ejøx im
4. wb¤^vw` P‚b© 29. imivR im
5. cyl¨vbyM P‚b© 30. †kŠwbZvM©j im
6. wm‡Zvcjvw` P‚b© 31. †kv_ Kvjvbj im
7. wnsMv÷K P‚b© 32. Kc~©i im
8. Bme¸j 33. kÖx ivgevb im
9. wmwjgvwib 34. †hv‡M›`ª im
10. hgvbx AK© 35. gvwbK¨ im
11. i‡mvbvw` K¡v_ 36. k¦vm Kvm wPšÍvgwb
12. †Mvÿzivw` K¡v_ 37. e„nr evZ wPšÍv gwb
13. `kgyj K¡v_ 38. kÖx K…ò PZzg©~L
14. gnvksL ewU 39. gKiaŸR imvqb
15. Ak¦©ni ewU 40. eRª ÿvi
16. iRt cÖeZ©bx ewU 41. jxjv wejvm
17. P›`ªcÖfv eUx 42. bvi`xq gnvjÿx wejvk
18. wbevib eUx 43. g„Zz¨Äq im
19. k~j ewRªbx eUx 44. f‚e‡bk¦i
20. b‡M›`ª eUx 45. e„nr evZ MRv¼zk
21. cÖfKi eUx 46. e„nr e‡½k¦i im
22. KÉ m~av 47. emšÍ KzmygvKi im
23. Av‡ivM¨ ea©bx 48. e„nr c~Y©P›`ª im
24. AwMœKzgvi im (MÖnYx) 49. Agwø cËvšÍK im
25. gnvivR b„cwZejøf 50. bevqm †jŠn
51. ¸WzP¨vw` †jŠn 76. evmKvwi÷

52. eiæbv`¨ †jŠn 77. gnv`ªvÿvwi÷
53. avÎx †jŠn 78. AR©ybvwi÷
54. cÖìvšÍK †jŠn 79. A‡kvKvwi÷
55. wccjv`¨ †jŠn 80. mvwiev`¨wi÷
56. k~jivR †jŠn 81. Lwìvwi÷
57. hK…ìx †jŠn 82. RxiKv`¨wi÷
58. KvsKvqb ¸woKv 83. †jŠnvme
59. e„nr †hvMivR ¸M¸jy 84. ivmœvme
60. beKvwl©K ¸j¸jy 85. c~YY©fvmb
61. evZvwi ¸M¸jy 86. gwÄôvme
62. cÂwZ³ N„Z ¸M¸jy 87. mvwiev`¨me
63. wmsnbv` ¸M¸jy 88. Dkxivmi
64. fvMx© ¸o 89. cÎv½vme
65. AvgjKx imvqb 90. P›`bvme
66. eªvÿx imvqb 91. Aiwe›`vme
67. mÄxebx imvqb 92. KbKvme
68. KzURvwi÷ 93. cÖmvibx mÜvb
69. gy¯ÍKvwió 94. PëbcÖvk
70. Aeqvwi÷ 95. nwiZKx LÛ
71. Ag„Zvwi÷ 96. fv¯‹i jeb
72. †ivwnZKvwi÷ 97. e„nr gwiP¨vw` ˆZj
73. Ak¦MÜvwi÷ 98. e„nr Kvwkmv`¨ ˆZj
74. ejvwi÷ 99. MÜK gjg
75. `kgyjvwi÷ 100. evZ ivÿzmx ˆZj
cwiwkó-3
AZ¨vekxKxq BDbvbx Jl‡ai ZvwjKv t
(List of Essential Unani Medicine)
µwgK Jl‡ai †RwbwiK bvg Dosage
bs Form
1 2 3
01 GwÎdj DmZzL~`~m (Etrifal Ustukhudus) Avav-KwVb
02 GwÎdj Kvk&bxhx (Etrifal Kashnizi) Avav-KwVb
03 GwÎdj evw`qvb (Etrifal Badian) Avav-KwVb
04 GwÎdj gywKj (Etrifal Muqil) Avav-KwVb
05 GwÎdj mK&gywbqv (Etrifal Saqmunia) Avav-KwVb
06 GwÎdj hgvbx (Etrifal Zamani) Avav-KwVb
07 GwÎdj kvn&Zviv (Etrifal Shahatara) Avav-KwVb
08 GwÎdj gywÛ (Etrifal Mundi) Avav-KwVb
09 GwÎdj Kexi (Etrifal Kabir) Avav-KwVb
10 GwÎdj ¸``x (Etrifal Gudadi) Avav-KwVb
11 Lvgxiv Ave‡ikg/Ave‡ikg Avikv`x (Khamira Avav-KwVb
Abresham/Abresham Arshadi)
12 Lvgxiv LvkLvk& (Khamira Khashkhash) Avav-KwVb
13 Lvgxiv MvIRevb (Khamira Gawjaban) Avav-KwVb
14 Lvgxiv MvIRevb Av¤îx (Khamira Gawjaban Ambari) Avav-KwVb
15 Lvgxiv gviIqvix`/Av‡bvk`v‡iv wjjyÕfx (Khamira Marwareed/ Avav-KwVb
Anoshdaro Liluvi)
16 Lvgxiv hn&i‡gvniv (Khamira Zaharmohara) Avav-KwVb
17 Lvgxiv ebdkv (Khamira Banafsha) Avav-KwVb
18 Lvgxiv bvh&jx (Khamira Nazli) Avav-KwVb
19 RIqvwik D` Zzk© (Jowarish Ood Tursh) Avav-KwVb
20 RIqvwik D` wkixb (Jowarish Ood Shireen) Avav-KwVb
21 RIqvwik Kg~bx Kexi (Jowarish Kamuni Kabir) Avav-KwVb
22 RIqvwik Kz›`yi (Jowarish Kundur) Avav-KwVb
23 RIqvwik KziZzg (Jowarish Qurtum) Avav-KwVb
24 RIqvwik hiDbx (Jowarish Zarooni) Avav-KwVb
1 2 3
25 RIqvwik hvwikK (Jowarish Zarishk) Avav-KwVb
26 RIqvwik kvn&‡iquvi (Jowarish Shahreyaran) Avav-KwVb
27 RIqvwik Rvjxb~m (Jowarish Jalinoos) Avav-KwVb
28 RIqvwik dvjvwdjx (Jowarish Falafili) Avav-KwVb
29 RIqvwik gyQZMx (Jowarish Mustagi) Avav-KwVb
30 RIqvwik Avgjv (Jowarish Amla) Avav-KwVb
31 RIqvwik Kg~bx (Jowarish Kamuni) Avav-KwVb
32 RIqvwik Zgi wn›`x (Jowarish Tamar Hindi) Avav-KwVb
33 RIqvwik wemevmv (Jowarish Bishbasa) Avav-KwVb
34 RIqvwik hvÄvexj (Jowarish Zanjabeel) Avav-KwVb
35 RIqvwik kvnx (Jowarish Shahi) Avav-KwVb
36 `vIqvDj-wgm&K gyÕZvw`j (Dawaul Misk Mutadil) Avav-KwVb
37 gvÕRyb AvKei (Majoon Aqbar) Avav-KwVb
38 gvÕRyb AvIRv/AvhvivKx (Majoon Awja/Azaraqi) Avav-KwVb
39 gvÕRyb Avi‡` †Lvigv (Majoon Arad-e Khorma) Avav-KwVb
40 gvÕRyb Ik&ev/P‚ePxbx (Majoon Ushba/Choobchini) Avav-KwVb
41 gvÕRyb QvÕjve/gyg&wmK (Majoon Sa’lab/Mumsik) Avav-KwVb
42 gvÕRyb dvjv‡mdv (Majoon Falasefa) Avav-KwVb
43 gvÕRyb myiÄvb (Majoon Suranjan) Avav-KwVb
44 gvÕRyb †mvnvMïuV (Majoon Sohagsoonth) Avav-KwVb
45 gvÕRyb †gvMvwjøR (Majoon Mughalliz) Avav-KwVb
46 gvÕRyb nvRiæj qvn~` (Majoon Hazrul Yahood) Avav-KwVb
47 gvÕRyb nvgj Av¤îx (Majoon Humal Ambari) Avav-KwVb
48 gvÕRyb èx`yj Iqv`© (Majoon Dabeedul Ward) Avav-KwVb
49 gvÕRyb bvbLvn& (Majoon Nankhah) Avav-KwVb
50 gvÕRyb mycvwicvK (Majoon Suparipak) Avav-KwVb
51 gvÕRyb †hvMivR †Mv¸j (Majoon Jograj Gogul) Avav-KwVb
52 gvÕRyb ivnvZ (Majoon Rahat) Avav-KwVb
53 gvÕRyb jvbv (Majoon Lana) Avav-KwVb
54 gvÕRyb KvjKvjvbvR& (Majoon Kalkalanaj) Avav-KwVb
1 2 3
55 gvÕRyb Lì (Majoon Khadar) Avav-KwVb
56 gvÕRyb Lì/hexe (Majoon Khadar/Jabeeb) Avav-KwVb
57 gvÕRyb kxi Avd&hv (Majoon Seer Afza) Avav-KwVb
58 gvÕRyb m½`vbv (Majoon Sangdana) Avav-KwVb
59 jDK Avgj&Zvm (Laooq Amaltas) Avav-KwVb
60 jDK G¨vRwgb (Laooq Asthmin) Avav-KwVb
61 jDK ev`vg (Laooq Badam) Avav-KwVb
62 jDK KvZvb/mv‡c¯Ívb (Laooq Katahw/Sapistan) Avav-KwVb
63 jDK `vgvfxb/RxKzb& bvdvm& (Laooq Damavin/Zeequnnafas) Avav-KwVb
64 jyeye Kexi (Lubub Kabir) Avav-KwVb
65 jyeye QMxi (Lubub Saghir) Avav-KwVb
66 nvjIqv QvÕjve/eqRv (Halwa Sa’lab/Baiza) Avav-KwVb
67 Kzk&Zv AveiK wmqvn& (Kushta Abrak Siyah) f®§
68 Kzk&Zv Kjqx (Kushta Qalyee) f®§
69 Kzk&Zv Q`d (Kushta Sadaf) f®§
70 Kzk&Zv wR¯Í (Kushta Jist) f®§
71 Kzk&Zv dIjv` (Kushta Faulad) f®§
72 Kzk&Zv eqRv (Kushta Baiza) f®§
73 Kzk&Zv evivwmsNv (Kushta Barasingha) f®§
74 Kzk&Zv gviIqvix` (Kushta Marwareed) f®§
75 Kzk&Zv gviRvb (Kushta Marjan) f®§
76 Kzk&Zv hni‡gvniv (Kushta Zahrmohra) f®§
77 Kzk&Zv nvRiæj&-qvn~` (Kushta Hajrul Yahood) f®§
78 Kzk&Zv †MŠ`šÍx (Kushta Gowdanti) f®§
79 Kzk&Zv eym&my`& (Kushta Bussud) f®§
80 Kzk&Zv gviRvb RIqv‡ni`vi (Kushta Marjan Jawahirdar) f®§
81 Kzk&Zv hg&i&i`/qvke (Kushta Zamurrad/Yashab) f®§
82 Kzk&Zv Dmiæe (Kushta Usrub) f®§
83 Kzk&Zv wgiMv½ (Kushta Mirgang) f®§
84 Kzk&Zv gyQvjøvQ& (Kushta Musallas) f®§
1 2 3
85 Kzk&Zv wZjv (Kushta Tila) ˆZj
86 Kzk&Zv byK&iv (Kushta Nuqra) f®§
87 Av‡e bgK wkixb (Aab-e Namak Shireen) Zij
88 AviK Avdmvb&Zxb& (Arq Afsanteen) Zij
89 AviK AvRIqvBb (Arq Ajwain) Zij
90 AviK evw`qvb (Arq Badian) Zij
91 AviK P~ePxbx (Arq Choobchini) Zij
92 AviK bvbLvn& (Arq Nankhah) Zij
93 AviK dIwjb (Arq Faulin) Zij
94 AviK †evLvi (Arq Bokhar) Zij
95 AviK gvDj-jvn&g/jvn&wgbv (Arq Maul-Lahm/Lahmina) Zij
96 AviK gynvwjøj (Arq Muhallil) Zij
97 AviK eibRvm~d (Arq Baranjasuf) Zij
98 kieZ Avb&‡Revi (Sharbat Anjebar) Zij
99 kieZ Avihvbx/Ibœve (Sharbat Arzani/Unnab) Zij
100 kieZ KvKbvR (Sharbat Kaknaj) Zij
101 kieZ wRwiqvbx (Sharbat Jiryani) Zij
102 kieZ wRbwmb/g‡fh (Sharbat Jinsin/Mavez) Zij
103 kieZ w`gvMx (Sharbat Dimaghi) Zij
104 kieZ gywì (Sharbat Mudir) Zij
105 kieZ gyb&wWb (Sharbat Mundin) Zij
106 kieZ Zvgvwiw·b (Sharbat Tamarixin) Zij
107 kieZ GRvh (Sharbat Ejaz) Zij
108 kieZ Luvmxbv (Sharbat Khansina) Zij
109 kieZ Ikev (Sharbat Ushba) Zij
110 kieZ KvB‡jvwmb (Sharbat Chylosin) Zij
111 kieZ `xbvi (Sharbat Deenar) Zij
112 kieZ wKiwgb (Sharbat Kirmin) Zij
113 kieZ gyQvd&dx (Sharbat Musaffi) Zij
1 2 3
114 kieZ bvh&jv (Sharbat Nazla) Zij
115 kieZ bxj~di (Sharbat Neelofar) Zij
116 kieZ dIjv` (Sharbat Faulad) Zij
117 kieZ eyh~ix (Sharbat Buzuri) Zij
118 kieZ mvbZviv (Sharbat Santara) Zij
119 kieZ †ej‡Mix (Sharbat Belgiri) Zij
120 kieZ wbm&Iqvb (Sharbat Niswan) Zij
121 kieZ wbmv (Sharbat Nisa) Zij
122 kieZ kvn&Kv (Sharbat Shahqa) Zij
123 kieZ †kdv (Sharbat Shefa) Zij
124 kieZ wgQvjx (Sharbat Misali) Zij
125 kieZ g‡fR (Sharbat Mavez) Zij
126 kieZ †me (Sharbat Seb) Zij
127 kieZ †QnvZ-Avdhv (Sharbat Shehat Afza) Zij
128 kieZ AvZ&dvj (Sharbat Atfal) Zij
129 kieZ wZd&wjb (Sharbat Tiflin) Zij
130 kieZ Zj&L (Sharbat Talkh) Zij
131 kieZ Z~Z (Sharbat Toot) Zij
132 gviIqvix` mvBqvj (Marwareed Saiyal) Zij
133 KziQ AvQ&di (Qurs Asfar) U¨ve‡jU
134 KziQ wRqvweZ (Qurs Ziabit) U¨ve‡jU
135 KziQ gyKveŸx Lvm/gyevn&nx (Qurs Muqavvi Khas/Mubahhi) U¨ve‡jU
136 KziQ gyb&vkwkd (Qurs Munashshif) U¨ve‡jU
137 KziQ gynvh&whj (Qurs Muhazzil) U¨ve‡jU
138 KziQ mvqjvb (Qurs Sailan) U¨ve‡jU
139 KziQ mvjvRxZ (Qurs Salajeet) U¨ve‡jU
140 KziQ Gn&†Zjvg (Qurs Ehtelam) U¨ve‡jU
141 KziQ ¸jbvi (Qurs Gulnar) U¨ve‡jU
142 KziQ eiQxbv (Qurs Barsina) U¨ve‡jU
1 2 3
143 KziQ nvRwgbv (Qurs Hazmina) Zij
144 KziQ BbdzRv (Qurs Infuza) U¨ve‡jU
145 KziQ †cwPk (Qurs Pechish) U¨ve‡jU
146 KziQ hnxi (Qurs Zaheer) U¨ve‡jU
147 KziQ ew›`k (Qurs Bandish) U¨ve‡jU
148 KziQ g~jvB‡qb (Qurs Mulayin) U¨ve‡jU
149 KziQ AvIRv (Qurs Awja) U¨ve‡jU
150 KziQ `x`vb (Qurs Deedan) U¨ve‡jU
151 KziQ jvihxb (Qurs Larzin) U¨ve‡jU
152 Mvwj©K cvj©m (Garlic Pearls) U¨ve‡jU
153 nv‡eŸ AvhvivKx (Habb-e Azaraqi) U¨ve‡jU
154 nv‡eŸ Avn&gi (Habb-e Ahmar) U¨ve‡jU
155 nv‡eŸ Av¤î †gvwgqvqx (Habb-e Ambar Momiyaee) U¨ve‡jU
156 nv‡eŸ BqvwiR (Habb-e Iyariz) U¨ve‡jU
157 nv‡eŸ IQviv/kieZ mvbv (Habb-e Usara/Sharbat Sana) U¨ve‡jU
158 nv‡eŸ wKe&ixZ (Habb-e Kibreet) U¨ve‡jU
159 nv‡eŸ Kv_ (Habb-e Kath) U¨ve‡jU
160 nv‡eŸ RÌqvi (Habb-e Jadwar) U¨ve‡jU
161 nv‡eŸ Ry›` (Habb-e Jund) U¨ve‡jU
162 nv‡eŸ Zvevkxi (Habb-e Tabasheer) U¨ve‡jU
163 nv‡eŸ wZiBqvKx/wZiBqvK Qvgvwbqv (Habb-e Tiryaqi/Tiryaq Samania) U¨ve‡jU
164 nv‡eŸ †Znvj (Habb-e Tehal) U¨ve‡jU
165 nv‡eŸ wbkvZ (Habb-e Nishat) U¨ve‡jU
166 nv‡eŸ gv`vi (Habb-e Madar) U¨ve‡jU
167 nv‡eŸ i‡mŠZ (Habb-e Rasaut) U¨ve‡jU
168 nv‡eŸ kve&Bqvi (Habb-e Shabyar) U¨ve‡jU
169 nv‡eŸ mvjvZxb (Habb-e Salateen) U¨ve‡jU
170 nv‡eŸ gybBk/gyg&wmK (Habb-e Munish/Mumsik) U¨ve‡jU
1 2 3
171 nv‡eŸ qviKvb (Habb-e Yarkan) U¨ve‡jU
172 nv‡eŸ wZbKvi/Ikev (Habb-e Tinkar/Usba) U¨ve‡jU
173 nv‡eŸ nvqvZxb gyiv°ve RIqv‡n`vi (Habb-e Hayateen) U¨ve‡jU
174 nv‡eŸ ûgv (Habb-e Humma) Zij
175 nv‡eŸ evIqvmxi `gfx (Habb-e Bawaseer Damavi) U¨ve‡jU
176 nv‡eŸ gyiv°ve (Habb-e Murrakab) Zij
177 nv‡eŸ evIqvmxi ev`x (Habb-e Bawaseer Badi) U¨ve‡jU
178 nv‡eŸ gywì (Habb-e Mudir) U¨ve‡jU
179 nvR‡gvj (Hazmol) Zij
180 ging/AviK AvRxe (Marham/Arq Ajeeb) gjg
181 ging K~ev (Marham Quba) gjg
182 ging/iIMb Lvwik (Marham Rowghan Kharish) gjg
183 ging bIwib (Marham Naurin) gjg
184 ging †mvwiqvwmb (Marham Soriasin) gjg
185 ging Av‡ZkK (Marham Ateshak) gjg
186 ging `v‡Lwjqyb (Marham Dakheliyoon) gjg
187 iIMb Avgjv/fv½iv (Rowghan Amla/Bhangra) ˆZj
188 iIMb m~L©/m~iÄvb (Rowghan Surkh/Suranjan) ˆZj
189 iIMb Rviwe‡bvj (Rowghan Jarbinol) ˆZj
190 iIMb PvnvieM©/wem&Lvc&iv (Rowghan Chaharburg) ˆZj
191 wZjv gyKveŸx/gRjyK (Tila Muqavi/Majlooq) ˆZj
192 KzZzi AvBwib/ivgv` (Qutoor Ainin/Ramad) Zij
193 wRgv` eiQ (Jimad Bars) cvDWvi
194 wZjv gyk&Kx/gyKveŸx LvQ (Tila Mushki/Muqavvi Khas) ˆZj
195 wZjv ksid (Tila Shangraf) ˆZj
196 wZjv gyKveŸx/ksid (Tila Muqavvi/Shagraf) ˆZj
197 eikvÕkv (Barshasa) Avav-KwVb
198 BqvwiR dvqKiv (Iyariz Faiqra) cvDWvi
1 2 3
199 ûjvm kv¤§x/jvLjvLv gyÕAvZvi (Hulas Shammi/Lakhlakha Muattar) ˆZj
200 RIqv‡ni †gvniv (Jawahir Mohra) f®§
201 RInix (Jawhari) f®§
202 RIni Kvd~i (Jawhar Kafoor) f®§
203 RIni mxb (Jawhar Seen) f®§
204 md~d B`&ivi (Sufoof Idrar) cvDWvi
205 md~d Bb&†ZQvex (Sufoof Intesabi) cvDWvi
206 md~d ¸ogvi (Sufoof Gurmar) cvDWvi
207 md~d wRwiqvb (Sufoof Jiriyan) cvDWvi
208 md~d bgKxb (Sufoof Namkin) cvDWvi
209 md~d gyb&`vwgj (Sufoof Mundamil) cvDWvi
210 md~d m~hvK/M‡Yvwib (Sufoof Suzak/Gonorin) cvDWvi
211 md~d MøvBwmb (Sufoof Glycin) cvDWvi
212 md~d gydvZ&wZZ& (Sufoof Mufattit) cvDWvi
213 md~d Avn&gixb (Sufoof Ahmarin) cvDWvi
214 md~d Kjqx Kzk&Zv (Sufoof Qayhee Kushta) cvDWvi
215 md~d gymvw¤§b (Sufoof Musammin) cvDWvi
216 md~d gymvw°b (Sufoof Musakkin) cvDWvi
217 md~d m½-wkKb (Sufoof Sang-Shikan) cvDWvi
218 md~d mvqvwUb/myiÄvb (Sufoof Suiatin/Suranjan) cvDWvi
219 md~d nvixiv (Sufoof Hareera) cvDWvi
220 myg©v gyKveŸx eQi (Surma Muqavvi Basar) cvDWvi
221 mbyb cvBIwib/evejv (Sufoof Pyorin/Babla) cvDWvi
222 hyiƒi gyRd&wdd& (Zuroor Mujaffif) cvDWvi
223 dihvRv Kv‡eR (Farzaja Qabiz) cvDWvi
cwiwkó-4
List of Essential Drugs
(Homoeopathic Medicine)
Potency Medicine (Potencies: 3X, 6X, 6, 12, 30, 200, 1M, 10M)
SL Name of Medicine SL Name of Medicine

1 Abrotanum 23 Arg. Nit
2 Absinthinum 24 Arg. Met
3 Aconitum nap 25 Aur. Met
4 Actea Racemosa 26 Bacillinum
5 Acalypha India 27 Badiaga
6 Aesculus M 28 Baptisia T
7 Agaricus M 29 Belladonna
8 Alumina 30 Benzoic acid
9 Allium Cepa 31 Bar. Carb
10 Aloe Soc 32 Baryta mur
11 Ammonium Carb 33 Berberis Vulgaris
12 Ammonium Mur 34 Bellis per
13 Ammonium Phos 35 Bismuth
14 Angus tura vera 36 Bovista
15 Antimonium Crud 37 Borax
16 Antimonium Tart 38 Bryonia alb
17 Anacardium 39 Bromium
18 Anthracinum 40 Bufo rana
19 Apis Mel 41 Camphora
20 Apocynum 42 Carcinsin
21 Arsenicum album 43 Calc carb
22 Arnica mont 44 Calendula

45 Cannabis indica 70 Croton tig
46 Causticum 71 Crotalus Horridus
47 Cactus G 72 Colocynthis
48 Capsicum 73 Cundurango
49 Carbo veg 74 Cuprum met
50 Carbolic acid 75 Digitalis
51 Carbo animalis 76 Dioscorea
52 Calc fluor 77 Diphtherinum
53 Calc phos 78 Drosera
54 Cantharis 79 Dulcamara
55 Caulophyllum 80 Equisetum
56 Carduas mar 81 Formica rufa
57 Cedron 82 Eupatorium perf
58 China off 83 Euphrasia
59 China ars 84 Ferrum met
60 China Sulfh 85 Flouric acid
61 Chamomilla 86 Gelsemium
62 Chelidonium 87 Glonoine
63 Cina 88 Graphites
64 Cicuta vir 89 Guaiacum
65 Cocculus ind 90 Hamamelis vir
66 Coca 91 Helleborus
67 Coffea Crud 92 Hepar sulph
68 Colchicum 93 Hippoz aenium
69 Conium mac 94 Hyoscyamus

95 Hydrocotyle A 120 Lyssin
96 Hydrasitis can 121 Mag carb
97 Hypericum 122 Mag phos
98 Ipecacuanha 123 Medorrinum
99 Ignatia 124 Merc sol
100 Iris ten 125 Merc sulph
101 Iris ver 126 Mezerum
102 Iodium 127 Mercuris
103 Kali bich 128 Millefolium
104 Kali Carb 129 Mur. Acid
105 Kali sulph 130 Murex
106 Kali bromatum 131 Mygale
107 Kali cyanatum 132 Naja tri
108 Kali Iod 133 Nat mur
109 Kali Mur 134 Nat phos
110 Kalmia lat 135 Nat carb
111 Kresotum 136 Nat sulph
112 Lapis albus 137 Nat ars
113 Lachesis 138 Nit acid
114 Lac Can 139 Nux vom
115 Lac defloratum 140 Nyctanhes arb
116 Ledum pal 141 Opium

117 Lilium tig 142 Oleander
118 Lobelia inflata 143 Petroleum
119 Lycopodium 144 Phoshorus

145 Phosphoric acid 172 Spigellia
146 Phytolacca 173 Staphisagria
147 Physostigma 174 Stramonium
148 Platina 175 Stannum met
149 Plumbum met 176 Sulphur
150 Podophyllum 177 Sulphuric acid
151 Prunus spinosa 178 Symphytum
152 Psorinum 179 Teucrium M.V
153 Pulsatilla 180 Tellurium
154 Pyrogenium 181 Thuja occi
155 Randunculus Bulb 182 Tarentula Cub
156 Rhatnia 183 Terebinthina
157 Rhus-tox 184 Thyroidinum
158 Rhododendron 185 Trillum Pendulum
159 Robina 186 Trombidium
160 Ruta gr. 187 Tuberculinum
161 Rumex crispus
188 Urtica urenus
162 Sabal Serrulata
189 Nran Nit
163 Sabina
190 Ustilago
164 Sangunaria
191 Verat alb
165 Sarsaprilla
192 Virat Viride
166 Selenium
193 Vipera tor.
167 Secale corr
194 Viburnum op
168 Senecio arueus
169 Sepia 195 Viscum alb
170 Silicea 196 Wyethia

171 Spongia tosta 197 Zinc met
Mother Tincture Mother Tincture

1. Abies Can 26. Cantharis
2. Aconitum Nap 27. Capsicum An
3. Actaea Rac 28. Carduus Mar
4. Aesculus Hip 29. Caulophyllum T
5. Agnus Cast 30. Ceanothus Amer
6. Alfalfa (Medicago sativa) 31. Chaparro Am
7. Allium Cepa 32. Chelidonium Maj
8. Allium Sat 33. China Off (Cinchona)
9. Aloe Soc 34. Chionanthus
10. Anacardium Ori 35. Cimicifuga
11. Apis Mel 36. Cina
12. Aralia Race 37. Cinnamonum
13. Arnica mont 38. Coca
14. Asafoetida 39. Coffea Crude
15. Avena sat 40. Colchicum A
16. Azadirachta Ind 41. Collinsonia Can
17. Baptisia Tinc 42. Colocynthis
18. Bellodonna 43. Condurango
19. Berberis Aqu 44. Crataegus Ox
20. Berberis Vul 45. Croton Tiglium
21. Blatta ori 46. Cyclamen
22. Bryonia Alb 47. Damiana (Turneva)
23. Buchi (Psoralea cor) 48. Digitalis P
24. Caladium Sac 49. Dioscorea V
25. Calotropis G 50. Dolichos P
Mother Tincture Mother Tincture

51. Drosera R 76. Phytolocca D
52. Echinacea A 77. Pinus Lamp
53. Ephedra N 78. Plantago M
54. Fraxinus A 79. Podophyllum
55. Fucus Vesi 80. Pulsatilla
56. Gelsemium
81. Quassia
82. Rhus Tox
57. Ginseng
83. Robinia
58. Gossypium
84. Sabal Serr
59. Guaiacum
85. Sabina
60. Gymnenma Syl (Mesasragi)
86. Salix Nigra
61. Hamamelis Ver
87. Sambucus Can
62. Helonias Dio
88. Sanguinaria Can
63. Hydrastic can
89. Secale Corr
64. Hydrocotyle A
90. Senecion A
65. Jaborandi
91. Stramonium
66. Jonosia Asoka
92. Syzygium Jamb
67. Justicia Ad.
93. Teucrium Mv
68. Lycopodum
94. Thuja Occ.
69. Millefolium
95. Tribulus T
70. Mullein Oil (Verbascum Thab) 96. Urtica Urens
71. Myristica 97. Viburnum Opu
72. Nuphar Lut 98. Viburnum Pru
73. Nux Vomica 99. Xanthoxylum
74. Ocimum Canum 100. Yohimbinum
75. Passiflora Inc 101. Zingiber
Biochemic (12 Tissue Salt (Potencies 3X, 4X, 6X, 12X)
Sl. No. Name of Medicine Sl. No. Name of Medicine

1. Kali Phos 7. Kali Mur
2. Calc Phos 8. Nat Mur
3. Nat. Phos 9. Kali Sulph
4. Ferrum Phos 10. Nat Sulph
5. Mag Phos 11. Calc Sulph
6. Silicea 12. Calc. Flour.
TRITURATION (Powder & Tablet)

Sl. No. Name of Medicine Sl. No. Name of Medicine
1. Acid Chryso 14. Acetanilide
2. Ammon Phos 15. Ars Sulp Flav
3. Antim Crud 16. Ephedrine
4. Borax 17. Sulphur
5. Carbo Veg 18. Ammon Benz
6. Cholesterinum 19. Hecla Lava
7. Graphites 20. Selenium
8. Gun Powder 21. Glonoinum
9. Ova Tosta 22. Aurum Mur Nat
10. Antim Tart 23. Kali Bichrom
11. Heper Sulph 24. Uranium Nit
12. Merc Sol 25. Arsenic lod
13. Titanium
External Applicational Only

Sl. Name of Medicine Sl. Name of Medicine
1. Mullen Oil 4. Plantago Maj Q
2. Euphrasia eye drops 5. Kreosote Q
3. Cineraria M succus eye drops
Ointment/Cream
Sl. Name of Medicine Sl. Name of Medicine
1. Calendula 7. Hamamelis
2. Cantharis 8. Aesculus Hip
3. Rhus tox 9. Berberis
4. Bryonia 10. Petroleum
5. Ledum pal 11. Arnica
6. Graphities
BIOCHEMIC COMBINATION TABLETS

COMPOSITION OF THE DRUGS (each tablet contains all drugs in equal
quantities)
1. No. 1 : Cal Phos 3X, Ferrum Phos 3X, Nat. Mur. 3X, Kali Phos 3X
2. No. 2 : Kali Phos 3X, Mag. Phos 3X, Nat. Mur. 3X, Nat Sulf 3X
3. No. 3 : Mag. Phos 3X, Cal Phos 3X, Nat Sulf 3X, Ferrum Phos 3X
4. No. 4 : Cal Flour 3X, Kali Mur, 3X, Nat Mur 3X, Silicea 3X
5. No. 6 : Ferrum Phos 3X, Kali Mur 3X, Mag Phos 3X, Nat Mur 3X,
Nat Sulf 3X
6. No. 7 : Cal Phos 3X, Ferrum Phos 3X, Kali Mur 3X, Nat Phos 3X,
Nat Sulf 3X
7. No. 9 : Ferrum Phos 3X, Kali Mur 3X, Kali Phos 3X, Mag Phos 3X
8. No. 10 : Cal Phos 3X, Ferrum Phos 3X, Kali Mur 3X
9. No. 12 : Ferrum Phos 3X, Nat Mur 3X, Kali Phos 3X, Mag Phos 3X
10. No. 13 : Cal Phos 3X, Kali Sulf 3X, Kali Phos 3X, Nat Mur 3X
11. No. 15 : Cal Phos 3X, Ferrum Phos 3X, Kali Phos 3X, Mag Phos 3X,
Kali Sulf 3X
12. No. 17 : Cal Flour 3X, Kali Phos 3X, Ferrum Phos 3X, Kali Mur 3X
13. No. 19 : Ferrum Phos 3X, Mag Phos 3X, Kali Sulf 3X, Nat Sulf 3X
14. No. 20 : Cal Flour 3X, Cal Sulf 3X, Kali Sulf 3X, Nat Mur 3X, Nat
Sulf 3X.
15. No. 23 : Ferrum Phos 3X, Mag Phos 3X, Cal Flour 3X
16. No. 24 : Cal Phos 3X, Ferrum Phos 3X, Kali Phos 3X, Mag Phos 3X,
Nat Phos 3X
17. No. 25 : Nat Phos 3X, Nat Sulf 3X, Silicea 3X
18. No. 26 : Mag Phos 3X, Cal Phos 3X, Kali Phos 3X, Cal Flour 3X
19. No. 27 : Nat Mur 3X, Kali Phos 3X, Cal Phos 3X,
cwiwkó-5
eë¯’vcÎwenxb Jl‡ai ZvwjKv (A¨v‡jvc¨vw_K)

(List of Over-the-Counter (OTC) Drugs (Allopathic)
1. Albendazole Chewable Tablet
2. Antacid Chewable Tablet/Suspension
3. Ascorbic Acid Chewable Tablet/Syrup
4. Benzyl Benzoate Lotion
5. Calcium Tablet
6. Chloramphenicol Eye/Ear Ointment/Drops
7. Chlorhexidine Lotion/Cream
8. Chlorisylenol Lotion/Cream
9. Chlorpheniramine Maleate Tablet/Syrup
10. Condoms
11. Diclofenac Gel
12. Dextromethorphen Syrup
13. Ferrous (Sulphate, Gluconate & Fumarate Tablet/Capsule/Syrup
14. Gentian Violet
15. Glycerin Suppository
16. Low Dose Contraceptive Pills
17. Mebendazole Tablet
18. Mebendazole Tablet/Suspension
19. Methyl Salicylate Gel
20. Milk of Magnesia Suspension

21. Mouthwash Preparations
22. Multivitamin Tablet/Capsule/Drops
23. Neomycin/Gentamycin/Bacitracin or combination Ointment/Cream/

Dusting Powder
24. Omeprazole capsule
25. Oral Rehydration Salt (ORS) (with or without glucose or flavours) Sachets
26. Paracetamol/Acetaminophen Tablet/Syrup/Suspension/Suppository
27. Permethrin Ointment/Cream
28. Potassium Permenganate Granules for Gargle
29. Povidone Iodine
30. Promethazine Theoclae Tablet
31. Ranitidin Tablet
32. Riboflavine Tablet
33. Salbutamol Tablet
34. Salicylic Acid + Benzoic Acid Ointment
35. Silver Sulphadiazine Ointment
36. Sunscreen Preparations
37. Vitamin A Capsule
38. Vitamin B Complex (individual or combination) Tablet/Syrup/Drops
39. Xylometazoline 0.1% Nasal Drops

cwiwkó-6
eë¯’vcÎwenxb Avqy‡e©w`K Jl‡ai ZvwjKv
(List of Over-the-Counter (OTC) Ayurvedic Drugs)
1. Zvwjkvw` P~Y©
2. gnvksL ewU
3. A¤øwcËvšÍK im
4. bevqm †jŠn
5. eªv²x imvqb
6. mÄxebx imvqb
7. KyURvwió
8. gy¯ÍKvwió
9. Afqvwió
10. Ag„Zvwi÷
11. †ivwnZKvwió
12. Ak¦MÜvwió
13. ejvwió
14. `kgyjvwió
15. gnv`ªvÿvwió
16. A‡kvKvwió
17. mvwiev`¨wió
18. †jŠnvme
19. cÎv½vme
20. P›`bvme
21. Aiwe›`vme
22. nwiZKx LÛ
23. evZ ivÿzmx ˆZj
cwiwkó-7
eë¯’vcÎwenxb Jl‡ai ZvwjKv (BDbvbx)
List of Over-the-Counter (OTC) Drugs (Unani)
µwgK bs Generic Name/Jl‡ai †R‡bwiK bvg Dosage Form
1 GwÎdj Dm&Z~L~`~m (Etrifal Ustukhudus) Avav-KwVb
2 GwÎdj gywKj (Etrifal Muqil) Avav-KwVb
3 GwÎdj Kvkbxhx (Etrifal Kashnizi) Avav-KwVb
4 GwÎdj kvnZviv (Etrifal Shahtara) Avav-KwVb
5 GwÎdj gywÛ (Etrifal Mundi) Avav-KwVb
6 GwÎdj hgvbx (Etrifal Zamani) Avav-KwVb
7 RIqvwik Kg~bx (Jowarish Kamuni) Avav-KwVb
8 RIqvwik Kz›`yi (Jowarish Kundur) Avav-KwVb
9 RIqvwik heDbx (Jowarish Zarooni) Avav-KwVb
10 RIqvwik Rvjxb~m (Jowarish Jalinoos) Avav-KwVb
11 RIqvwik gš‘Mx (Jowarish Mastagi) Avav-KwVb
12 gvÕRyb dvjv‡mdv (Majoon Falasefa) Avav-KwVb
13 gvÕRyb Avi‡` †Lvigv (Majoon Arad-e-Khurma) Avav-KwVb
14 gvÕRyb AvhvivKx (Majoon Azaraqi) Avav-KwVb
15 gvÕRyb Ik&ev (Majoon Ushba) Avav-KwVb
16 gvÕRyb èx`yj Iqv`© (Majoon Dabeedul ward) Avav-KwVb
17 gvÕRyb dvjv‡mdv (Majoon Falasifa) Avav-KwVb
18 gvÕRyb Kz›`yi (Majoon Kundur) Avav-KwVb
19 gvÕRyb wcuqvR (Majoon Piyaz) Avav-KwVb
20 gvÕRyb †mvnvMïuV (Majoon Sahagsonth) Avav-KwVb
21 gvÕRyb m~iRvb (Majoon Suranjan) Avav-KwVb
22 jDK KvZvb (Laooq Katan) Avav-KwVb
23 jDK mv‡c¯Ívb (Laooq Sapistan) Avav-KwVb
24 AviK †evLvi (Arq Bukhar) Zij

25 AviK `kg~j (Arq Dashmool) Zij
26 AviK AvRxe (Arq Ajeeb) Zij
27 AviK †Mvjve (Arq Gulab) Zij
28 AviK Kvmbx (Arq Kasni) Zij
29 AviK gv‡Kv (Arq Mako) Zij
30 kieZ eyh~ix (Sharbat Buzuri ) Zij
31 kieZ Ibœve (Sharbat Unnab ) Zij
32 kieZ `xbvi (Sharbat Deenar) Zij
33 kieZ evmK (Sharbat Vasac) Zij
34 kieZ GRvh (Sharbat Ejaz) Zij
35 kieZ bxj~di (Sharbat Neelofar) Zij
36 kieZ dIjv` (Sharbat Faulad) Zij
37 kieZ gyQvd&dx (Sharbat Musaffi) Zij
38 kieZ nvRwgbv (Sharbat Hazmina) Zij
39 kieZ nvqvZxb gyiv°ve (Sharbat Hayatin Murakkab) Zij
40 †mKvÄvexb mv`v ( Sikanjabeen) Zij
41 kieZ mvb&Zviv (Sharbat Santara) Zij
42 kieZ eyh~ix †gvZvw`j (Sharbat Bazoori Motadil) Zij
43 kieZ †ej‡Mix (Sharbat Belgiri) Zij
44 kieZ KzowP (Sharbat Kurchi) Zij
45 kieZ wKk&Iqvi (Sharbat Kishwar) Zij
46 kieZ †me (Sharbat Seb) Zij
47 kieZ wbm&Iqvb (Sharbat Niswan) Zij
48 kieZ Z~Z wmqvn (Sharbat Toot Siyah) Zij
49 KziQ ew›`k (Qurs Bandish) U¨ve‡jU
50 KziQ Mvwj©U¨ve (Qurs Garlitab) U¨ve‡jU
51 KziQ nvR‡gvj (Qurs Hazmol) U¨ve‡jU

52 KziQ cyw`bv (Qurs Pudina) U¨ve‡jU
53 KziQ †cwPk (Qurs Pechish) U¨ve‡jU
54 KziQ `x`vb (Qurs Deedan) U¨ve‡jU
55 KziQ gyjvB‡qb (Qurs Mulayin) U¨ve‡jU
56 nv‡eŸ û¤§v (Habb-e Humma) U¨ve‡jU
57 nv‡eŸ †kdv (Habb-e Shefa) U¨ve‡jU
58 KziQ gyKveŸx LvQ (Qurs Muqavvi Khas) U¨ve‡jU
59 KziQ Gn&‡Zjvg (Qurs Ehtelam) U¨ve‡jU
60 KziQ mvjvRxZ (Qurs Salajeet) U¨ve‡jU
61 KziQ AvQ&di (Qurs Asfar) U¨ve‡jU
62 KziQ K~ev (Qurs Quba) U¨ve‡jU
63 KziQ Kvd~i (Qurs Kafoor) U¨ve‡jU
64 KziQ g~jvB‡qb (Qurs Mulaiyin) U¨ve‡jU
65 KziQ G AvdmvbZxb (Qurs Afsanteen) U¨ve‡jU
66 nv‡eŸ †nj&ZxZ (Habb-e Helteet) U¨ve‡jU
67 nv‡eŸ Kv‡e` †bŠkvìx (Habb-e Kabid Naushadri) U¨ve‡jU
68 nv‡eŸ wZb&Kvi (Habb-e Tinkar) U¨ve‡jU
69 nv‡eŸ nvqvZxb (Habb-e Hayateen) Zij
70 nv‡eŸ LyeQzj&-nv`x` (Habb-e Khubsul Hadeed) U¨ve‡jU
71 nv‡eŸ RÌqvi (Habb-e Jadwar) U¨ve‡jU
72 nv‡eŸ wbkvZ (Habb-e Nishat) U¨ve‡jU
73 nv‡eŸ wRwiqvb (Habb-e Jiryan) U¨ve‡jU
74 nv‡eŸ gybBk (Habb-e Munish) U¨ve‡jU
75 nv‡eŸ myiÄvb (Habb-e Suranjan) U¨ve‡jU
76 nv‡eŸ gywì (Habb-e Mudir) U¨ve‡jU
77 nv‡eŸ AvdwZgyb (Habb-e Aftimon) U¨ve‡jU
78 nv‡eŸ WveŸv AvZdvj (Habb-e Dabba-e-Atfal) U¨ve‡jU

79 nv‡eŸ nvgj (Habb-e Hamal) U¨ve‡jU
80 nv‡eŸ RIqvwni (Habb-e Jawahid) U¨ve‡jU
81 nv‡eŸ Ry›` (Habb-e Jund) U¨ve‡jU
82 nv‡eŸ KiÄyqv (Habb-e Karanjwa) U¨ve‡jU
83 nv‡eŸ bvhjv (Habb-e Nazla) U¨ve‡jU
84 nv‡eŸ ivj (Habb-e Rall) U¨ve‡jU
85 nv‡eŸ i‡mŠZ (Habb-e Rasaut) U¨ve‡jU
86 nv‡eŸ myidv (Habb-e Surfa) U¨ve‡jU
87 nv‡eŸ Zvevmxi (Habb-e Tabashir) U¨ve‡jU
88 ging K~ev (Marham Quba ) gjg
89 ging Lvwik (Marham Kharish) gjg
90 iIMb m~L© (Rowghan Surkh) ˆZj
91 wZjv Rv`x` ( Tila Jadeed) ˆZj
92 md~d mvqjvb (Suffof Sailan) cvDWvi
93 md~d Zxb (Suffof Tenn) cvDWvi
94 md~d ûg~wRb (Suffof Humuzin) cvDWvi
95 md~d Ryiwnb (Suffof Jurhin) cvDWvi
96 Av‡e bgK wkixb (Aab-e Namak Shireen) cvDWvi
97 Kvd~i mvBqvj (Kafoor Saiyal) cvDWvi
98 mb~b cvBIwib (Sanoon Pyorin) cvDWvi
ivóªcwZi Av‡`kµ‡g
†MŠZg Kzgvi
DcmwPe|
†gvt Avãyj gv‡jK, DccwiPvjK, evsjv‡`k miKvix gy`ªYvjq, †ZRMuvI, XvKv KZ…©K gyw`ªZ|
†gvt AvjgMxi †nv‡mb, DccwiPvjK, evsjv‡`k dig I cÖKvkbv Awdm,
†ZRMuvI, XvKv KZ…©K cÖKvwkZ| website: www.bgpress.gov.bd

Evsjv 'K M Ru: Iwr÷Vw© Bs WW G-1

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Evsjv 'K M Ru: Iwr÷Vw© Bs WW G-1

Uploaded by

Copyright:

Available Formats

†iwR÷vW© bs wW G-1

e„n¯úwZevi, gvP© 23, 2017

MYcÖRvZš¿x evsjv‡`k miKvi

ÒRvZxq Jla bxwZ, 2016Ó

DbœZ †`‡ki Jla wbqš¿YKvix cÖwZôv‡bi wbKU †_‡K Good Manufacturing

2| RvZxq JlabxwZi jÿ¨mg~n

2.4| †`‡ki Drcvw`Z Jl‡ai ißvwb e„w× Kiv|

3| RvZxq JlabxwZi Dcv`vbmg~n

3.15| DbœZ †`kmg~‡ni Av`‡j mvaviYfv‡e e¨env‡ii †ÿ‡Î e¨e¯’vcÎ-wenxb wbivc`

(M) Avg`vbxi Rb¨ wbeÜb

mswkøó Jla GKB cY¨bv‡g wb¤œewY©Z Kgc‡ÿ GKwU DbœZ †`‡k

4.5 Jla I Jl‡ai KuvPvgv‡ji Drcv`b

(S) cÖhyw³ n¯ÍvšÍi A_ev be-D™¢vweZ Jlamg~‡ni jf¨Zv wbwðZ Kivi

(Z) `ÿZv e„w×i Rb¨ Jla cÖkvmb Awa`ß‡ii cwi`k©K‡`i wbqwgZ

4.6 RvZxq Jla wbqš¿Kvix KZ…©cÿ (National Regulatory Authority-NRA)

(M) Jla cÖkvmb Awa`ßi‡K WHO-Gi Accreditated Ges PIC/S-Gi

(N) RvZxq Jla wbqš¿YKvix KZ…©c‡ÿi AvBbMZ welqvw` Kvh©Kifv‡e

(O) RvZxq Jla wbqš¿YKvix KZ…©c‡ÿi I‡qemvBU wbqwgZfv‡e nvjbvMv`

4.7 bKj, †fRvj I wb¤œgv‡bi Jla cÖ¯‘Z, weµq I weZiY †iva

(O) Avqy‡e©w`K, BDbvbx, nvev©j I †nvwgIc¨vw_K-ev‡qv‡KwgK Jl‡ai

4.11 †`‡k bZzb cÖhyw³ I KvwiMwi Ávb n¯ÍvšÍi

4.13 dvg©v‡KvwfwR‡jÝ A_ev Jl‡ai weiƒc cÖwZwµqvmg~‡ni (Adverse Drug

4.14| Jla Drcv`bKvix cÖwZôv‡bi `ÿ Rbej

(L) Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jla

4.15| Jla ißvwb

(R) mÿg M‡elYv ms¯’v wn‡m‡e AvaywbK I Uª¨vwWkbvj Jl‡ai cixÿv,

4.17| A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx I †nvwgIc¨vw_K Jl‡ai Rb¨ Avjv`v

4.19| Avqy‡e©w`K, BDbvbx, nve©vj, †nvwgIc¨vw_K I ev‡qv‡KwgK Jl‡ai gvb

(K) Jlwa¸Y m¤úbœ Dcv`vbhy³ I †ivM wb‡`©kK…Z Ges dvg©vwmDwUK¨vj

(L) DwjøwLZ Food or Nutritional or Herbal or Natural

4.21| †gwW‡Kj wWfvBm I mvwR©K¨vj BKzBc‡g›U Avg`vwb

(K) kix‡ii Af¨šÍ‡i Ges evB‡i †hme †gwWK¨vj wWfvBm I mvwR©K¨vj

(L) †gwWK¨vj wWfvBm I mvwR©K¨vj BKzBc‡g›U Avg`vwbi Rb¨

4.22| Jl‡ai wK¬wbK¨vj Uªvqvj (Clinical Trial) I ev‡qvBKzf¨v‡jÝ cixÿY

Jl‡ai ¸YMZ gvb I Kvh©KvwiZv m¤ú‡K© wbwðZ nIqvi j‡ÿ¨ Jl‡ai

4.23| WTO/TRIPS Pzw³i Av‡jv‡K evsjv‡`‡ki Jla wkíweKv‡k mnvqZv Kiv

4.24| Lv`¨ I Jla cÖkvmb Awa`ß‡i iƒcvšÍi I mvsMVwbK KvVv‡gv cybwe©b¨vm

4.26| cÖvwYm¤ú` I grm¨ wPwKrmvq e¨eüZ Jla

(M) Rb¯^v‡¯’¨i Rb¨ ÿwZKi A¨v‡jvc¨vw_K, Avqy‡e©w`K, BDbvbx, nve©vj,

RvZxq JlabxwZ-2005 ch©v‡jvPbv K‡i JlabxwZ-2016 cÖYqb Kiv n‡q‡Q| G

10. MEDICINES AFFECTING THE BLOOD

12. CARDIOVASCULAR MEDICINES

12.2 Antiarrhythmic medicines

12.3 Antihypertensive medicines

13.3 Anti-inflammatory and antipruritic medicines

18. HORMONES, OTHER ENDOCRINE MEDICINES AND

18.6 Ovulation inducers

216 BCG Vaccine

217 DPT Vaccine

218 Pentavalent vaccine (DPT, HepatitiesB, Hib)

219 Pneumococcal Vaccine (PCV)

220 Poliomyelitis Vaccine(OPV & IPV)

221 MR Vaccine (Mesales & Rubella)

222 Measles vaccine Injection

223 Hepatitis-B Vaccine Injection

20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND

235 Phenylephrine Hydrochloride Eye Drops

24.1 Medicines used in psychotic disorders

24.3 Medicines for anxiety disorders

51. ¸WzP¨vw` †jŠn 76. evmKvwi÷

SL Name of Medicine SL Name of Medicine

SL Name of Medicine SL Name of Medicine

SL Name of Medicine SL Name of Medicine